Animal food composition
By using animal food compositions of glycyrrhizin and curcumin compounds, the shortcomings in the treatment and prevention of allergic inflammatory skin diseases in the prior art are solved, effective management of atopic dermatitis is achieved, and drug dependence is reduced and Side effects, significantly improving skin health.
Patent Information
- Application Number
- CN202080048687.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-07-02
- Filing Date
- 2020-07-01
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-07-01
AI Technical Summary
The prior art is difficult to effectively treat and prevent allergic inflammatory skin diseases, especially atopic dermatitis, and common drugs have significant side effects and high costs, and treatment for diseases often only controls individual aspects rather than providing long-term relief or cure.
Animal food compositions containing licorice and curcumin compounds are prepared into coarse grinds or protein-containing compositions for the prevention and treatment of allergic inflammatory skin diseases, including atopic dermatitis.
It significantly reduced the severity and frequency of itching, reduced dependence on drugs, provided benefits for skin health, and significantly affected CADESI-04 and PVAS scores within 3 months, improving the skin condition of the animals.
Smart Images

Figure BDA0003452481480000031 
Figure BDA0003452481480000041 
Figure BDA0003452481480000161
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority from European patent application EP 19183974.5 filed on July 2, 2019, which is incorporated herein by reference in its entirety. Technical Field
[0003] The present disclosure relates to the field of animal food compositions for preventing and / or treating allergic inflammatory skin diseases. Background Art
[0004] Allergic inflammatory skin diseases are chronic conditions characterized by clinical symptoms such as erythema, pain, redness, swelling, small blisters or papules on the skin. They are the second most common allergic skin disease in animals, especially dogs, second only to flea allergies. These allergic reactions can be caused by normally harmless substances such as grasses, mold spores, house dust mites and other environmental allergens.
[0005] The main symptoms of allergic inflammatory skin diseases are skin inflammation and itching, often associated with scratching and exfoliation in affected animals caused by an interaction of genetic and environmental factors. Allergic symptoms manifest as eczema of the skin, and animals such as dogs with atopic dermatitis often suffer from itching or severe itching, hair loss, exfoliation of the epidermis due to deep scratching, frequent licking of the paws, and excessive tear production. Secondary skin problems such as skin infections and excessive sebum secretion are also common.
[0006] More specifically, atopic dermatitis is one of the most common allergic inflammatory skin diseases. Several approaches to treat atopic dermatitis and pruritus have been described, including the use of ultramicronized palmitoylethanolamide (Noli et al.; Vet Dermatol 2015;26, 432-40) or antihistamines such as fexofenadine or drugs such as cyclosporine. However, most of the available drugs are not suitable for long-term use due to significant side effects (and in many cases, prohibitive costs). Although, if allergens are identified, immunotherapy can improve symptoms, the success rate remains variable. The ability to reduce drug dependence would be seen as a valuable contribution to the field and is a major goal of nutritional intervention.
[0007] Indeed, there is now evidence that genetic predisposition appears to influence the immune system as well as functional / structural aspects of the skin barrier. Known environmental components are the allergen load and the microbial population present on the skin. Medications currently prescribed for this condition target separate aspects of the disease process, often immune related, but only manage the disease rather than provide long-term relief or a cure. Nutritional management strategies are more likely to be successful if they target multiple aspects simultaneously.
[0008] Therefore, there remains a need for treatment options for allergic inflammatory skin diseases such as atopic dermatitis.
[0009] There is also a need for alternative natural products for the treatment or prevention of such diseases.
[0010] Therefore, there remains a need for novel diets designed to improve immune function and barrier defense. Summary of the invention
[0011] A first aspect of the present disclosure relates to an animal food composition comprising: (i) a source of glycyrrhizin, in combination with (ii) a source of one or more curcuminoids, for use in a method of preventing and / or treating allergic inflammatory skin diseases.
[0012] A second aspect of the present disclosure relates to a kit comprising (i) a first part comprising a source of glycyrrhizin, and (ii) a second part comprising a source of one or more curcuminoids, for use in a method of preventing and / or treating allergic inflammatory skin diseases.
[0013] A third aspect of the present disclosure relates to an animal food composition comprising: (i) a source of glycyrrhizin, in combination with (ii) a source of one or more Curcuminoids; wherein the animal food composition is a kibble and / or wherein the animal food composition comprises a source of protein.
[0014] A fourth aspect of the present disclosure relates to a method of making an animal food composition comprising a source of glycyrrhizin in combination with a source of one or more Curcuminoids, the animal food composition being kibble and / or the animal food composition comprising a source of protein, the method comprising at least the steps of: a) mixing the source of glycyrrhizin and the source of one or more Curcuminoids to provide a mixture; and b) heating the mixture.
[0015] Another aspect of the present disclosure relates to the use of a source of glycyrrhizin and a source of one or more Curcuminoids; a kit for preparing a composition comprising a source of glycyrrhizin and a source of one or more Curcuminoids; and a composition for preparing an animal food composition comprising: (i) a source of glycyrrhizin, in combination with (ii) one or more sources of Curcuminoids; wherein the animal food composition is a kibble and / or the animal food composition comprises a source of protein.
[0016] In certain embodiments, the one or more Curcuminoids present in the animal food composition or kit disclosed herein are compounds of formula (I), pharmaceutically acceptable salts thereof, tautomers thereof, or stereoisomers thereof:
[0017]
[0018] Among them, R 1 and R 2 In some other embodiments, the one or more curcuminoids are selected from the group consisting of curcumin, demethoxycurcumin, methoxycurcumin, tetrahydrocurcumin and combinations thereof.
[0019] In certain embodiments, the animal food compositions disclosed herein are nutritionally complete animal food compositions.
[0020] In certain embodiments, the source of glycyrrhizin in the animal food composition of the present disclosure is licorice, and / or the source of one or more Curcuminoids in the animal food composition is turmeric.
[0021] In certain embodiments, the animal food composition disclosed herein further comprises linoleic acid. In certain other embodiments, the animal food composition further comprises EPA / DHA, taurine, lutein, vitamin E, or a combination thereof.
[0022] In certain embodiments, the animal food compositions disclosed herein are used to treat and / or prevent an allergic inflammatory skin disease selected from the group consisting of atopic dermatitis, flea allergic dermatitis, urticaria, angioedema, inhalant allergy, inhalant allergic dermatitis, food allergic dermatitis, contact dermatitis, miliary dermatitis, eosinophilic granuloma, head and neck pruritus, and generalized pruritus.
[0023] In certain embodiments, the present disclosure is directed to an animal food composition comprising a combination of a source of glycyrrhizin and a source of one or more Curcuminoids, wherein the animal food composition consists of kibble and / or the animal food composition further comprises a source of protein. In certain embodiments, the animal food composition is a nutritionally complete food composition. In certain embodiments, the source of glycyrrhizin in the animal food composition and / or kit of the present disclosure is licorice and the source of one or more Curcuminoids is turmeric.
[0024] In certain embodiments, the present disclosure provides a method for preventing and / or treating allergic inflammatory skin diseases in an animal in need thereof, wherein the method comprises administering an animal food composition comprising a source of glycyrrhizin and a source of one or more Curcuminoids. In certain embodiments, the one or more Curcuminoids are compounds of formula (I), pharmaceutically acceptable salts thereof, tautomers thereof, or stereoisomers thereof:
[0025]
[0026] Among them, R 1 and R 2 In some specific embodiments, the one or more curcuminoids are selected from the group consisting of curcumin, demethoxycurcumin, methoxycurcumin, tetrahydrocurcumin and combinations thereof. In some embodiments, the source of glycyrrhizin is licorice. In some specific embodiments, the animal food composition comprises licorice and turmeric. In some embodiments, the animal food composition further comprises linoleic acid, EPA / DHA, taurine, lutein, vitamin E or combinations thereof.
[0027] In certain embodiments, the allergic inflammatory skin disease is selected from the group consisting of atopic dermatitis, flea allergy dermatitis, urticaria, angioedema, inhalation allergy, inhalation allergic dermatitis, food allergy dermatitis, contact dermatitis, miliary dermatitis, eosinophilic granuloma, head and neck pruritus, and generalized pruritus. In certain embodiments, the animal is a canine. In certain specific embodiments, the canine is a dog. DETAILED DESCRIPTION
[0028] The present disclosure aims to provide a product for preventing and / or treating allergic inflammatory skin diseases, especially atopic dermatitis, i.e. canine atopic dermatitis, in animals, especially dogs.
[0029] The present disclosure herein provides an animal food composition comprising a combination of a source of glycyrrhizin and a source of Curcuminoids.
[0030] Surprisingly, it has been shown that this animal food composition can act on the progression of itching, erythema, pain, redness, swelling, small vesicles or papules in animals. The efficacy of the composition is determined based on three results: CADESI-04, PVAS (itch visual analog scale) and drug score.
[0031] As shown in the examples herein, when provided to animals with allergic inflammatory skin diseases, such as animals with atopic dermatitis (e.g., canine atopic dermatitis), the animal food compositions of the present disclosure are well tolerated and significantly affect CADESI-04, PVAS, and drug scores after 3 months, and, in particular, the animal food compositions also have a significant effect on PVAS within the first month of treatment.
[0032] In certain embodiments, as shown in the present disclosure, the combination of a source of glycyrrhizin and a source of one or more Curcuminoids provides benefits in animal skin health, for example, in animals suffering from allergic inflammatory skin diseases. In certain specific embodiments, the animal suffers from atopic dermatitis, for example, canine atopic dermatitis.
[0033] In certain other embodiments, as shown in the present disclosure, the combination of the above ingredients provides benefits in the skin health of animals. In specific embodiments, the animal suffers from allergic inflammatory skin diseases. In certain specific embodiments, the animal suffers from atopic dermatitis, such as canine atopic dermatitis.
[0034] Furthermore, as shown in the present disclosure, the combination of the above ingredients significantly reduces the severity and frequency of pruritic flares, which is a primary symptom of the disease. Specifically, the diet has been shown to significantly reduce the dose and frequency of medication required to control the condition, i.e., reduce the severity of the condition to a level deemed acceptable by veterinarians and owners.
[0035] Thus, the present disclosure relates to animal food compositions or kits comprising a source of glycyrrhizin in combination with a source of curcuminoids. Such compositions or kits are useful for preventing and / or treating allergic inflammatory skin diseases in animals, and more specifically for animals suffering from atopic dermatitis. In certain embodiments, the animal is a canine. In certain specific embodiments, the animal is a dog.
[0036] More specifically, the present disclosure also provides an animal food composition. This object has been achieved by providing an animal food composition comprising a combination of a source of glycyrrhizin and a source of curcuminoids; the animal food composition is characterized in that it is in the form of kibble and / or it further comprises a source of protein.
[0037] definition
[0038] The terms used in this specification generally have their ordinary meaning in the art, within the context of the present disclosure and in the specific context in which each term is used. Certain terms are discussed below or elsewhere in the specification to provide additional guidance for describing the compositions and methods of the present disclosure and how to make and use them.
[0039] As used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a compound" includes a mixture of compounds.
[0040] The term "about" or "approximately", as used herein, means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, according to common practice in the art, "about" may mean within 3 or more standard deviations. Alternatively, "about" may mean a range of up to 10%, more preferably up to 5%, and more preferably still up to 1% of a given value.
[0041] As used herein, the terms "comprises," "comprising" or any other variations thereof are intended to cover a non-exclusive inclusion such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
[0042] In the detailed description herein, references to "an embodiment," "an embodiment," "one embodiment," "in embodiments," and the like indicate that one or more embodiments described may include a particular feature, structure, or characteristic, but each embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases do not necessarily refer to the same embodiment. In addition, when a particular feature, structure, or characteristic is described in conjunction with an embodiment, whether or not explicitly described, it is considered to be within the knowledge of those skilled in the art to affect such feature, structure, or characteristic in conjunction with other embodiments. After reading the specification, it will be apparent to those skilled in the relevant art how to implement the present disclosure in alternative embodiments.
[0043] As used herein, the term "enantiomers" refers to pairs of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture or racemate. Where appropriate, the term is used to refer to a racemic mixture.
[0044] As used herein, the term "enantiopure" refers to a sample that consists of a single enantiomer within the limits of detection.
[0045] As used herein, the term "diastereoisomer" refers to a stereoisomer having at least two asymmetric atoms but which is not a mirror image of each other. Absolute stereochemistry is specified according to the Cahn-Ingold-Prelog RS system. When a compound is a pure enantiomer, the stereochemistry of each chiral carbon can be specified by R or S. Resolved compounds with unknown absolute configuration can be specified as (+) or (-) according to the direction (right-handed or left-handed), in which direction they rotate plane polarized light with the wavelength of the sodium D line. The compounds of the disclosed subject matter contain one or more asymmetric centers, and therefore enantiomers, diastereomers and other stereoisomeric forms can be produced, which can be defined as (R)- or (S)- according to absolute stereochemistry. The currently disclosed subject matter is intended to include all these possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures. Optically active (R)- and (S)-isomers can be prepared using chiral synthons or chiral reagents or separated using conventional techniques. If the compound contains a double bond, the substituents may be in the E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituents may have a cis or trans configuration. All tautomeric forms are also intended to be included.
[0046] As used herein, the term "isomer" refers to different compounds with the same molecular formula but different arrangements and configurations of atoms. In addition, as used herein, the term "stereoisomer" refers to any of a variety of stereoisomeric configurations that can exist for a given compound of the disclosed subject matter, and includes geometric isomers. It should be understood that substituents can be attached to the chiral center of a carbon atom. Therefore, the term "stereoisomer" includes enantiomers, diastereomers, or racemates of a compound. In addition, as used herein, the term "structural isomer" refers to different compounds with the same number and type of atoms but different ways of connecting the atoms, such as, but not limited to, tautomers.
[0047] As used herein, the term "food composition" or "diet" encompasses all foods, diets, food supplements or materials that may contain protein, carbohydrates and / or crude fat. Food may also contain supplementary substances or additives, such as minerals, vitamins and condiments (see Merriam-Webster's Collegiate Dictionary, 10th edition, 1993). Such food compositions may be nutritionally complete or incomplete. In a particular embodiment, an animal food composition according to the present disclosure is a nutritionally complete food composition.
[0048] As used herein, "nutritionally complete" means that the composition provides a comprehensive and balanced nutritional requirement for an animal. In certain embodiments, such an animal is a dog. Therefore, a nutritionally adequate feed is a feed that the animal (e.g., the dog) can use as the only ration to be fed and can maintain life without additional food (except water). The food composition may include a carrier, a diluent, or an excipient. Depending on the intended use, a carrier, a diluent, or an excipient suitable for animal use may be selected. In certain embodiments, the animal is a canine. In certain specific embodiments, the animal is a dog. Typically, a nutritionally complete composition comprises at least one protein (or polypeptide) source, such as a protein extract, at least one vitamin, mineral, trace element, and fat source.
[0049] As used herein, "food supplement" refers to concentrated sources of nutrition, such as, but not limited to, vitamins and minerals, substances used for nutritional or physiological purposes, or plants and botanicals intended to compensate for deficiencies in the regular diet of an animal. In certain embodiments, food supplements are sold in the form of capsules, lozenges, tablets, pills, powder packets, or liquid forms (ampoules, vials with droppers).
[0050] As used herein, the term "drug" refers to any substance or composition represented as having therapeutic, curative or preventive properties against animal diseases. By extension, pharmaceutical products include any substance or composition that can be used or administered to animals for the following purposes: to make a medical diagnosis, or to restore, correct or modify the physiological function of an animal by exerting a pharmacological, immunological or metabolic effect.
[0051] Illustratively, a food composition as described herein may include, but is not limited to, protein, crude fat, ash, crude fiber, starch, calcium, phosphorus, sodium, chloride, potassium, magnesium, iron, water, copper, manganese, zinc, selenium, vitamin A, vitamin D3, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin B7, vitamin B9, choline chloride, arachidonic acid, W3 fatty acids, or W6 fatty acids.
[0052] As used herein, the term "animal" or "animals (plural)" means a ruminant, poultry, pig, mammal, horse, mouse, rat, rabbit, guinea pig, hamster, cow, cat or canine. In a specific embodiment, the animal is a canine. The term "animal" may refer more specifically to a non-human animal. It may refer to a domestic or wild animal. In certain embodiments, a non-human animal may be a pet animal. In certain embodiments, the pet animal is a cat or a canine. In certain specific embodiments, the canine is a dog.
[0053] For example, and not by way of limitation, the animal can be a penguin, falcon, agouti, American kestrel, snake, bear, condor, ant, impala, antelope, armadillo, Australian brush turkey, babirusa, bald eagle, Bali myna, fox, bat, sunbird, bee, beetle, bear, cat, binturong, bird of paradise, python, bonobo, bontebok, brown bear, caecilians, camels, caracals, chameleons, cheetahs, chimpanzees, chinchillas, cichlids, clouded leopards, cobras, cockatoos, crocodiles, eagles, jackals, dolphins, platypuses, echidnas, elephants, emus, flamingos, fossa, frogs, toads, Galapagos tortoises, baboons, giant anteaters, giant pandas, Gila monsters, giraffes, goats, sheep, frogs, gorillas, gouldian finch, guam rails, rail), guanaco, long-tailed monkey, hippopotamus, hornbill, ibis, iguana, jacana, jaguar, heron, kangaroo, wallaby, kingfisher, king snake, honey bear, kiwi, klipspringer, koala, koi, Komodo dragon, ladybug, kookaburra, lemur, leopard, lion, lizard, lynx, macaw, magpie goose, manatee, mandrill, white-browed monkey, marsupial, meerkat, metallic starling, monkey, ocelot, okapi, opossum, orangutan, eland, ostrich, otter, owl, African wild dog (painted dog, parrot, peacock, pelican, polar bear, porcupine, prairie dog, pronghorn antelope, Przewalski's horse, raccoon, white-bellied shelduck, red panda, reindeer, lappet, rock hyrax, saiga antelope, scorpion, sea lion, secretary bird, serval, siamang, snow leopard, spider, stork, sun bear, Suriname toad, takin, tapir, Tasmanian devil, hedgehog, tiger, toucan, lizard, turtle, vulture, warthog, striated finch, whale, cape buffalo, wolf, wombat, or zebra.
[0054] As used herein, the term "canine" includes animals including animals selected from the group consisting of wolves, coyotes, jackals, dingoes, jackals, foxes, raccoon dogs, and dogs (including pet animals). As used herein, dogs include wild dogs and domestic dogs. In certain specific embodiments, the dog is a domestic dog.
[0055] As used herein, the term "preventing" may also include reducing the likelihood of a given condition occurring or reoccurring in an animal.
[0056] As previously mentioned, allergic inflammatory skin diseases are characterized by the production of one or more of erythema, pain, redness, swelling, and small blisters or papules on the skin. Parts of the body commonly affected by atopic dermatitis include the head, auricles, feet, ventral abdomen, and armpits. As used herein, the term "allergic" refers to an unregulated or unregulated sensitivity of the immune system to normally harmless substances (e.g., those present in the environment), particularly hypersensitivity reactions. Common allergy triggers include, but are not limited to, airborne allergens such as pollen, animal dander, dust mites, and mold; certain foods such as peanuts, tree nuts, wheat, soy, fish, shellfish, eggs, and milk; insect stings, such as but not limited to bee or wasp stings; medications such as penicillin or penicillin-based antibiotics; latex or other substances that can cause allergic skin reactions; allergic inflammatory skin diseases such as atopic dermatitis, flea allergy dermatitis, urticaria, angioedema, inhalation allergy, inhalation allergic dermatitis, food allergy dermatitis, contact dermatitis, miliary dermatitis, eosinophilic granuloma, head and neck pruritus, and systemic pruritus. It will therefore be understood herein that the term "allergic" can be associated with both "auto-antigens" and exogenous antigens.
[0057] As used herein, the term "inflammation" refers to a local response to cellular injury manifested by capillary dilation, leukocyte infiltration, redness, heat, and pain.
[0058] It is known to those skilled in the art that allergic inflammatory skin diseases can be diagnosed in a variety of ways. Allergic inflammatory skin diseases can be diagnosed by measuring 3 results. As used herein, "3 results" refer to CADESI-04, PVAS (itch) and drug score.
[0059] As used herein, the term "CADESI-04" refers to the "Canine Atopic Dermatitis Extent and Severity Index" (Olivry et al., 2014; International Committe on Allergic Diseases of Animals (ICADA)), one of the scoring systems developed for diagnosing the severity of canine atopic dermatitis. CADESI-04 can also be used with the Canine Atopic Dermatitis Lesion Index to assess the extent of erythema, lichenoid sclerotic plaques, and excoriations. CADESI-04 is a stand-alone scoring system used to assess the likelihood that an animal has an allergic inflammatory skin disease, particularly atopic dermatitis, canine atopic dermatitis, and to assess the severity of the condition.
[0060] The pruritus visual analogue score (PVAS) was measured using the Hill pruritus visual analogue score (Hill et al., 2007). The PVAS was scored by a rater using an analogue scale from 0 to 10, with 0 representing no itch / chewing and 10 representing constant and intense itch / chewing.
[0061] The medication score or pharma score is based on a system developed and used by Litzbauer and colleagues (Litzlbauer P et al., 2014; Oral and subcutaneous treatment of canine atopic dermatitis with recombinant felineinterferon omega). The medication score allows the determination and quantification of the degree to which an animal's allergic inflammatory skin disease (e.g., atopic dermatitis in animals, such as atopic dermatitis in dogs) relies on medications or other pharmacological treatments to maintain quality of life at a level acceptable to the owner and veterinarian. Each medication was scored (Table 1A-Table 1D). Table 1A-D shows the medication scores for animals with atopic dermatitis and concomitant medications.
[0062] Table 1A
[0063] Drug treatment: score No concurrent medication 0 Shampoo Therapy 5 Ear medicine (external use) 5 Other topical treatments 5 Antihistamines 10 Frequent antibiotic use (>21 days) 20 Less frequent (< 21 days) 10
[0064] Table 1B
[0065] Prednisolone: score ≥1 mg / kg / d (milligrams / kilograms / day) 40 0.5 mg / kg / day–1 mg / kg / day 30 0.2 mg / kg / day–0.5 mg / kg / day 20 ≤ 0.2 mg / kg / day 10
[0066] Table 1C
[0067] Cyclosporin: (5 mg / kg) score SID (once a day) 30 EOD (every other day) 20 E3D (every three days) 10 E4D (every four days) 5
[0068] Table 1D
[0069] Oclacitinib: score BID (twice a day) 40 SID (once a day) 30 EOD (every other day) 20 E3D (every three days) 10
[0070] As used herein, the term "wet food" or "wet food composition" generally refers to a food composition having a moisture content of about 30% or more, typically greater than about 40%, relative to the total weight of the food composition. In certain specific embodiments, the wet food composition has a moisture content of less than about 90% by weight relative to the total weight of the food composition. Typically, it is the final product of a process that includes a terminal sterilization step (rather than a drying step). In a certain embodiment, the wet food is in the form of chunks, more specifically in the form of chunks in gravy. In certain specific embodiments, the wet food is in the form of chunks and gravy, chunks in jelly, loaf, mousse, terrine, bite.
[0071] "Chunk and gravy" products include a pre-made meat particle that is prepared by making a meat paste and passing the meat paste under pressure through a nozzle and then cooking. Products such as cooked meat are cut into large chunks and eventually mixed with a gravy or sauce. The two components are then filled into containers (usually cans or bags) and then sewn or sealed and sterilized. In contrast to ground meat loaves, chunk and gravy compositions are prepared with physically separated, discrete chunks (i.e., ground meat pieces and cereal pieces). These discrete particles are present in a gravy-type liquid in the final container. When served, the chunk and gravy product flows out of the can and can be easily mixed with other dry products. Although chunk and gravy products provide better integrity of the individual ingredients, the heterogeneous formulations of chunk and gravy products are sometimes unpopular with consumers.
[0072] Wet food compositions are typically packaged in canned containers and are considered "wet" in appearance due to the moisture contained therein. Two types of wet compositions are well known in the art. The first is known in the art as "ground loaf." Ground loaf products are typically prepared by contacting a mixture of components under heat to produce a substantially uniform intracellular honeycomb-type mass or "ground loaf." The ground loaf mass is then packaged into a cylindrical container, such as a can. When packaged, the ground loaf takes the shape of the container, so the ground loaf must be cut when provided to a companion animal.
[0073] In certain embodiments, the wet food composition is packaged. In this way, the consumer can identify the ingredients in the food product from the packaging and confirm that it is suitable for the particular pet in question. The packaging can be metal, plastic, paper or cardboard.
[0074] As used herein, the term "dry food" or "dry food composition" generally refers to a food or composition having a moisture content of less than about 12% by weight, and generally even less than about 7% by weight, relative to the total weight of the food composition. In certain specific embodiments, the dry food according to the present disclosure has a moisture content of up to about 12% by weight. In certain embodiments, the dry food has a moisture content of about 7% or less, such as about 5%, by weight. In certain specific embodiments, the dry food has a moisture content of greater than about 3% by weight relative to the total weight of the food composition. For example, the embodiments provided herein illustrate dry foods having a moisture content of about 9.5% by weight relative to the total weight of the food composition. In a certain specific embodiment, the dry food consists of kibble. In certain embodiments, for example but not limited to, kibble may include particles; pellets; pet food pieces, dehydrated meat, meat analogs, vegetables and combinations thereof; and pet treats, such as meat or vegetable jerky, rawhide and biscuits. The dry food composition can be manufactured by mixing and kneading the ingredients together to make a consistent dough that can be cooked. Typically, it can be the final product of a process that includes an extrusion step and a subsequent drying step.
[0075] The production process of dry food is usually completed by baking and / or extrusion. The dough is usually fed into a machine called an expander and / or extruder, which uses pressurized steam or hot water to cook the raw materials. When the dough is in the extruder, the dough is under extreme pressure and high temperature. The dough is then pushed through a die (a hole of a specific size and shape), and then cut off with a knife. The puffed dough pieces are passed through a dryer to make kibble, so that the moisture drops to a certain target, thereby ensuring that the food is stable until consumption. The kibble can then be sprayed with fat, oil, minerals, vitamins, natural extracts cocktail, and optionally sealed in a package. In some specific embodiments, the dry food composition is packaged. In this way, consumers can identify the ingredients in the food from the package and confirm that it is suitable for a specific pet, such as the dog in question. The packaging can be metal, plastic, paper or cardboard.
[0076] As used herein, the term "semi-wet food" or "semi-wet food composition" generally refers to a food composition having an intermediate moisture content of about 12% by weight to about 30% by weight relative to the total weight of the food composition. Therefore, such a semi-wet food composition is generally the final product of a process that allows a moisture content value between dry food and wet food. In certain embodiments, the process may include a step of adding a wetting agent. In certain embodiments, the process includes an extrusion step and a subsequent superheated steam (SHS) treatment step. In certain embodiments, relative to the total weight of the food composition, a semi-wet food according to the present disclosure comprises more than about 12% and up to about 30% moisture by weight. In certain embodiments, a semi-wet food composition has about 11% to about 20% moisture by weight relative to the total weight of the food composition, and / or a water activity of about 0.64 to about 0.75. In certain specific embodiments, a semi-wet food composition has about 11% to about 20% moisture by weight relative to the total weight of the food composition, and a water activity of about 0.64 to about 0.75.
[0077] As used herein, the term "water activity" refers to the ratio of the partial vapor pressure of water in a food composition divided by the standard state partial vapor pressure of water. Several methods known to the skilled person can be used to measure water activity, such as but not limited to resistance electrolysis, capacitance or dew point hygrometers. In certain specific embodiments, it refers to the method specified in the international standard ISO 21087 for determining water activity in animal food and animal feed.
[0078] As a non-limiting example, a super-heated steam (SHS) process such as the processes and methods described in published patent applications WO2009 / 018990, WO2009 / 018996, WO2010 / 112097, WO2014 / 122072, WO2016 / 071372 and / or WO2016 / 071367, the disclosures of which are incorporated herein in their entirety, may be used.
[0079] In a particular embodiment, when the animal food composition is a semi-moist food, it consists of soft semi-moist kibble.
[0080] According to certain embodiments, the moisture content of the animal food composition can be measured by a Loss on Drying Method, which comprises the following steps:
[0081] (a) weighing a sample of a food composition to obtain a total weight;
[0082] (b) heating the sample of step a) in an oven, for example, at 135±2° C. for 240 minutes, until all the water is removed, thereby obtaining a dry sample;
[0083] (c) weighing the dried sample to obtain a dry weight;
[0084] (d) Calculate the difference between the total weight and the dry weight to obtain the water weight, which is:
[0085] Water weight = (total weight) - (dry weight)
[0086] Unit
[0087] Unless otherwise indicated, all weight percentages expressed herein are by weight of the total weight of dry matter of the food composition.
[0088] As used herein, the amount of a component expressed as weight / Mcal consists of the amount by weight of that component in units of Metabolizable Energy (ME) of the total animal food composition.
[0089] As used herein, the ME parameter is intended to represent the energy value of a food composition that is metabolized directly after consumption. Within the scope of the present disclosure, the ME value may be measured by any suitable method known in the art.
[0090] Illustratively, ME values can be measured using a feeding trial. In practice, the gross energy (GE) of a food is determined in the laboratory, and the amount of food consumed by the animal is recorded. Feces and urine are collected from the animal, and the energy of each is determined, referred to as fecal energy (FE) and urinary energy (UE), respectively. ME can then be calculated as:
[0091] ME (kcal / kg) = [GE - (FE + UE)] / kg of food consumed.
[0092] Alternatively, the ME value can be measured by a mathematical method, in particular taking into account the percentages of crude fat (CF), crude protein (CP) and NFE (carbohydrates) in the composition. In practice, each percentage is multiplied by its respective Atwater Factors. The resulting sum is then multiplied by 10. The mathematical method can be represented by the following formula:
[0093] ME(kcal / kg)=10×[(3.5×CP)+(8.5×CF)+(3.5×NFE)].
[0094] Metabolizable energy can generally be determined according to standard methods, and in particular according to NRC, Nutrient requirements of dogs and cats, 2006, Academy Press, Washington, DC.
[0095] Components of food compositions
[0096] The food compositions and kits of the present disclosure can include a variety of components. Non-limiting examples of components that can be incorporated into the food compositions of the present disclosure are listed below.
[0097] Glycyrrhizin
[0098] In certain embodiments, the food compositions and / or kits described herein may include glycyrrhizin. As used herein, the term "glycyrrhizin" refers to a component of the root of Glycyrrhiza glabra (i.e., licorice or liquorice). Glycyrrhizin is the most prominent compound in licorice and is a triterpene glycoside. Licorice is a perennial plant that exists naturally or is cultivated in Europe and Asia. In addition, glycyrrhizin has a variety of pharmacological effects, such as anti-inflammatory, antiviral, antitumor, antioxidant and hepatoprotective activities (Sato et al., 1996; Rahman et al., 2006).
[0099] The structure of glycyrrhizin includes a triterpene part (glycyrrhetinic acid) and two iduronic acid residues. Other names for glycyrrhizin include glycyrrhizic acid, glycyrrhizic acid, glycyrrhetinic acid glycoside, and (3-beta,20-beta)-20-Carboxy-11-oxo-30-norolean-12-en-3-yl-2-O-beta-D-glucopyranuronosyl-alpha-Dglucopyranosiduronic acid.
[0100] Glycyrrhizin can be extracted from a variety of natural plants by several extraction techniques known to those skilled in the art, such as supercritical CO2 extraction, two-phase extraction, solvent extraction, third-phase extraction, microwave-assisted extraction or ultrasound-assisted extraction.
[0101] The CAS registration number of glycyrrhizin is 1405-86-3, and it is characterized by the following structure:
[0102]
[0103] In certain embodiments, the term "glycyrrhizin" as used herein may refer to a pharmaceutically acceptable salt thereof and / or one of its racemic, enantiomeric, diastereoisomeric or tautomeric forms.
[0104] Examples of pharmaceutically acceptable salts include, but are not limited to, ammonium salts such as monoammonium glycyrrhizinate, alkali metal salts such as disodium glycyrrhizinate, trisodium glycyrrhizinate, and dipotassium glycyrrhizinate.
[0105] Glycyrrhizin can be found in some naturally occurring extracts and / or plants, or obtained by chemical methods (Shabkhiz MA, Eikani MH, Bashiri Sadr Z, Golmohammad F. Superheated water extraction of glycyrrhizic acid from licorice root. Food Chem., 2016, 210: 396-401).
[0106] In certain embodiments, glycyrrhizin can be extracted from a source of glycyrrhizin (e.g., crude licorice). The source of glycyrrhizin can be an extract containing glycyrrhizin obtained from a plant material. In certain specific embodiments, an extract containing glycyrrhizin can be obtained from a plant material containing glycyrrhizin (e.g., crude licorice) by an extraction method comprising at least the following steps:
[0107] (a) providing plant materials containing glycyrrhizin;
[0108] (b) grinding the plant material of step a), preferably in a solvent, thereby obtaining a ground mixture;
[0109] (c) extracting glycyrrhizin from the ground mixture to obtain a glycyrrhizin-containing extract;
[0110] (d) optionally, filtering the glycyrrhizin extract to obtain a filtered glycyrrhizin extract;
[0111] (e) optionally, concentrating the filtered glycyrrhizin extract;
[0112] (f) optionally, spray drying the filtered glycyrrhizin extract to obtain a powder; and
[0113] (g) Optionally, the powder is sieved.
[0114] As used herein, "plant material containing glycyrrhizin" refers to a source of glycyrrhizin. In certain specific embodiments, the plant material containing glycyrrhizin refers to Glycyrrhiza glabraroot. In certain more specific embodiments, the plant material containing glycyrrhizin refers to a licorice extract containing glycyrrhizin or a crude licorice containing glycyrrhizin.
[0115] As used herein, the term "solvent" may refer to acetic acid, n-butanol, isopropanol, n-propanol, ethanol, methanol, formic acid, dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone, dichloromethane, tetrahydrofuran, ethyl acetate, n-hexane, benzene, toluene, ether, chloroform, 1,4-dichloroethane, In certain specific embodiments, the solvent is water.
[0116] In certain embodiments, the term "plants" or "plant" includes glycyrrhiza. Specifically, the genus Glycyrrhiza is selected from the group consisting of: glycyrrhiza acanthocarpa, glycyrrhiza aspera, glycyrrhiza astragalina, glycyrrhiza bucharica, glycyrrhiza echinate, glycyrrhiza eglandulosa, glycyrrhiza eurycarpa, glycyrrhiza foetida, glycyrrhiza foetidissima, glycyrrhiza frearitis, glycyrrhiza glabra, glycyrrhiza gontscharovii, glycyrrhiza iconica, glycyrrhiza inflata, glycyrrhiza korshinskyi, glycyrrhiza lepidota, glycyrrhiza spicata ... pallidiflora), glycyrrhiza squamulose, glycyrrhiza triphylla, glycyrrhiza uralensis and glycyrrhiza yunnanensis.
[0117] As used herein, the term "licorice" or "liquorice" includes crude licorice, licorice root, and Glycyrrhiza glabra root.
[0118] In certain embodiments, licorice may include about 1% to about 30% glycyrrhizin by weight relative to the total weight of licorice dry matter. In certain specific embodiments, licorice may contain about 5% to about 20% glycyrrhizin by weight. In certain more specific embodiments, licorice may include about 6% to about 20% glycyrrhizin by weight relative to the total weight of licorice dry matter.
[0119] According to certain embodiments, the licorice root may include about 1% or about 25% by weight of glycyrrhizin, based on the total weight of the licorice root dry matter.
[0120] According to certain specific embodiments, the licorice root may contain about 6% to about 12% glycyrrhizin by weight relative to the total weight of the licorice root dry matter. As used herein, about 6% to about 12% glycyrrhizin by weight, based on the total weight of the licorice root dry matter, includes about 6.0%, about 6.5%, about 7.0%, about 7.5%, about 8.0%, about 8.5%, about 9.0%, about 9.5%, about 10.0%, about 10.5%, about 11.0%, about 11.5% or about 12.0% glycyrrhizin by weight.
[0121] In certain embodiments, licorice can be provided from a commercially available source, such as Licorice Root PE 12% Glycyrrhizin Preparation provided by Naturex (Product No.; ED161596).
[0122] In a particular embodiment, the source of glycyrrhizin comprises liquorice or an extract thereof containing glycyrrhizin. Any other source of glycyrrhizin known to those skilled in the art may also be used, in particular any other source of glycyrrhizin other than liquorice. In certain embodiments, the source of glycyrrhizin may be pure glycyrrhizin.
[0123] Typically, the amount of glycyrrhizin in a given botanical source, extract, or food composition may be expressed in g / Mcal (grams per megacalorie), or by weight per total weight of dry matter of the given botanical source, extract, or composition.
[0124] In certain embodiments, the animal food composition or kit comprises a source of glycyrrhizin in an amount of about 0.01 g / Mcal to about 10 g / Mcal. In certain specific embodiments, the animal food composition or kit comprises a source of glycyrrhizin in an amount less than about 5 g / Mcal. In certain more specific embodiments, the animal food composition or kit comprises a source of glycyrrhizin in an amount less than about 2 g / Mcal. In certain more specific embodiments, the animal food composition or kit comprises a source of glycyrrhizin in an amount less than about 0.5 g / Mcal.
[0125] According to certain embodiments, the animal food composition or kit comprises a source of glycyrrhizin in an amount of about 0.01 g / Mcal to about 0.1 g / Mcal.
[0126] According to certain embodiments, the animal food composition or kit comprises a source of glycyrrhizin in an amount of about 0.01% to about 10% by weight relative to the total weight of dry matter of the animal food composition.
[0127] As used herein, about 0.01% to about 4% by weight of a source of glycyrrhizin, based on the total weight of dry matter of the animal food composition, includes about 0.01%, about 0.1%, about 1%, about 2%, about 3%, or about 4% by weight of a source of glycyrrhizin.
[0128] According to certain embodiments, the animal food composition or kit includes a source of glycyrrhizin in an amount ranging from about 0.01% to about 0.1% by weight based on the total weight of dry matter of the animal food composition.
[0129] As used herein, sources of about 0.01% to about 0.1% glycyrrhizin by weight, based on the total weight of dry matter of the animal food composition, include about: 0.01%, 0.011%, 0.012%, 0.013%, 0.014%, 0.015%, 0.016%, 0.017%, 0.018%, 0.019%, 0.02%, 0.021%, 0.022%, 0.023%, 0.024%, 0.025%, 0.026%, 0.027%, 0.028%, 0.029%, 0.030%, 0.031%, 0.032%, 0.033%, 0.034%, 0.035%, 0.036%, 0.037%, 0.038%, 0.039%, 0.040%, 0.041%, 0.042%, 0.043%, 0.044%, 0.045%, 0.046%, 0.047%, 0.048%, 0.049%, 0.050%, 0.051%, 0.052%, 0.053%, 0.054%, 0.055%, 0.056%, 0.057%, 0.058%, 0.059%, 0.060%, 0.061%, 0.062%, 0.063%, 0.064%, 0.065%, 0.066%, 0.067%, 0.068%, 0.069%, 0.070%, 0.071%, 0.072%, 0.073%, 0.074%, 0.075%, 0.07 0.027%, 0.028%, 0.029%, 0.03%, 0.031%, 0.032%, 0.033%, 0.034%, 0.035%, 0.036%, 0.037%, 0.038%, 0.039%, 0.04%, 0.041%, 0.042%, 0.043%, 0.044%, 0.045%, 0.046%, 0.047%, 0.048%, 0.049%, 0.05%, 0.051%, 0.052%, 0.053%, 0.054%, 0.055%, 0.056%, 0.057%, 0.058%, 0.059%, 0.06%, 0.061%, 0.062%, 0.063%, 0.064%, 0.065%, 0.066%, 0.067%, 0.068%, 0.069%, 0.07%, 0.071%, 0.072%, 0.073%, 0.074%, 0.075%, 0.076% , 0.077%, 0.078%, 0.079%, 0.08%, 0.081%, 0.082%, 0.083%, 0.084%, 0.085%, 0.086%, 0.087%, 0.088%, 0.089%, 0.09%, 0.091%, 0.092%, 0.093%, 0.094%, 0.095%, 0.096%, 0.097%, 0.098%, 0.099% or 0.1% of a source of glycyrrhizin.
[0130] Curcuminoids
[0131] In certain embodiments, the food compositions and / or kits described herein may include one or more Curcuminoids.
[0132] As used herein, the term "curcuminoids" refers to phenols present in the Indian spice turmeric. Turmeric is generally derived from the root of the plant Curcuma longa. Curcuminoids are also found in the roots of other species of the Zingiberaceae family of the genus Curcuma. In particular, turmeric may contain about 60% to about 80% by weight of curcumin relative to the total weight of turmeric dry matter, about 15% to about 30% by weight of demethoxycurcumin relative to the total weight of turmeric dry matter, and about 2% to about 6% by weight of bisdemethoxycurcumin relative to the total weight of turmeric dry matter. The curcuminoids in the food composition or kit of the present disclosure may be in any form, including powder or lipid extract.
[0133] In certain embodiments, Curcuminoids can be found in some naturally occurring extracts and / or plants, or obtained by chemical methods.
[0134] In a particular embodiment, the source of curcuminoids comprises turmeric extract, Curcuma Longa. A non-limiting example of a turmeric extract is turmeric extract from Arjuna Or turmeric extract from Naturex. Any other source of curcuminoids known to those skilled in the art may also be used.
[0135] Other sources of curcuminoids that can be used include, but are not limited to, liposomal curcumin, curcumin nanoparticles, curcumin phospholipid complexes (e.g., from MERIVA, about 20% total curcuminoids to BCM95 Arjuna, about 90% by weight of total curcuminoids), structural analogs of curcumin (e.g., EF-24) demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and commercial preparations / DM, as well as any formulation designed to increase the bioavailability of curcumin.
[0136] In certain embodiments, in addition to turmeric (Curcuma longa), curcuminoids can also be found in other botanicals, such as Curcuma xanthorrhiza and Curcuma zedoania. Curcuminoids in pure form are poorly soluble in water. Curcuminoids can be extracted from plants containing curcuminoids (such as turmeric root) using organic solvents (such as ethanol or acetone).
[0137] In certain embodiments, the curcuminoid compounds according to the present disclosure may include compounds of general formula (I), pharmaceutically acceptable salts thereof, tautomers thereof, and stereoisomers thereof:
[0138]
[0139] Where R 1 and R 2 are independently selected from hydrogen, methoxy, methyl, hydroxyl and ethoxy.
[0140] In certain embodiments, R 1 and R 2 In certain other embodiments, R 1 and R 2 are different.
[0141] In certain specific embodiments, the curcuminoid compound is selected from the group consisting of curcumin (II), demethoxycurcumin (III), bis-methoxycurcumin (IV), tetrahydrocurcumin (V), and combinations thereof. The structures of each compound (II)-(V) are provided below:
[0142]
[0143]
[0144] In a specific embodiment, the Curcuminoid compound is curcumin.
[0145] In a specific embodiment, the source of Curcuminoids (e.g., Curcumin) is turmeric.
[0146] According to certain embodiments, the animal food composition or kit comprises a source of Curcuminoids in an amount of about 0.01 g / Mcal to about 10 g / Mcal. In specific embodiments, the animal food composition or kit comprises a source of Curcuminoids in an amount of less than about 5 g / Mcal. In certain specific embodiments, the animal food composition or kit comprises a source of Curcuminoids in an amount of less than about 2 g / Mcal. In certain specific embodiments, the animal food composition or kit comprises a source of Curcuminoids in an amount of less than about 0.5 g / Mcal. In certain embodiments, the animal food composition or kit comprises a source of Curcuminoids in an amount of about 0.01 g / Mcal to about 0.1 g / Mcal.
[0147] In certain embodiments, the animal food composition or kit comprises a source of Curcuminoids in an amount of about 0.01% to about 10% by weight based on the total weight of dry matter of the food composition.
[0148] As used herein, about 0.01% to about 10% by weight of a source of Curcuminoids, based on the total weight of dry matter of the food composition, includes about 0.01%, about 0.1%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9% or about 10% by weight of a source of Curcuminoids.
[0149] In certain embodiments, the source of Curcuminoids may consist of pure Curcuminoids.
[0150] In certain embodiments, the animal food composition or kit comprises a source of Curcuminoids in an amount of about 0.01% to about 0.1% by weight relative to the total weight of dry matter of the animal food composition.
[0151] As used herein, about 0.01% to about 0.1% of a source of Curcuminoids, based on the total weight of dry matter of the animal food composition, includes about: 0.01%, 0.011%, 0.012%, 0.013%, 0.014%, 0.015%, 0.016%, 0.017%, 0.018%, 0.019%, 0.02%, 0.021%, 0.022%, 0.023%, 0.024%, 0.025%, 0.026%, 0.027%, 0.028%, 0.029%, 0.030%, 0.031%, 0.032%, 0.033%, 0.034%, 0.035%, 0.036%, 0.037%, 0.038%, 0.039%, 0.040%, 0.041%, 0.042%, 0.043%, 0.044%, 0.045%, 0.046%, 0.047%, 0.048%, 0.049%, 0.050%, 0.051%, 0.052%, 0.053%, 0.054%, 0.055%, 0.056%, 0.057%, 0.058%, 0.059%, 0.060%, 0.061%, 0.062%, 0.063%, 0.064%, 0.065%, 0.066%, 0.067%, 0.068%, 0.069%, 0.070%, 0.071%, 0.072%, 0.073%, 0.074%, 0.075%, 0.076 0.027%, 0.028%, 0.029%, 0.03%, 0.031%, 0.032%, 0.033%, 0.034%, 0.035%, 0.036%, 0.037%, 0.038%, 0.039%, 0.04%, 0.041%, 0.042%, 0.043%, 0.044%, 0.045%, 0.046%, 0.047%, 0.048%, 0.049%, 0.05%, 0.051%, 0. 0.052%, 0.053%, 0.054%, 0.055%, 0.056%, 0.057%, 0.058%, 0.059%, 0.06%, 0.061%, 0.062%, 0.063%, 0.064%, 0.065%, 0.066%, 0.067%, 0.068%, 0.069%, 0.07%, 0.071%, 0.072%, 0.073%, 0.074%, 0.075%, 0.076%, 0 0.077%, 0.078%, 0.079%, 0.08%, 0.081%, 0.082%, 0.083%, 0.084%, 0.085%, 0.086%, 0.087%, 0.088%, 0.089%, 0.09%, 0.091%, 0.092%, 0.093%, 0.094%, 0.095%, 0.096%, 0.097%, 0.098%, 0.099% or 0.1% of a source of Curcuminoids.
[0152] Other Ingredients
[0153] According to the first aspect of the present invention, the animal food composition or kit for preventing and / or treating allergic inflammatory skin diseases further comprises linoleic acid.
[0154] In certain embodiments, the animal food composition or kit further comprises EPA / DHA, taurine, lutein, vitamin E, and / or combinations thereof.
[0155] In certain embodiments, the animal food composition or kit may further include one or more vitamin A, vitamin B3, vitamin C, zinc, vitamin D, one or more fatty acids, and / or combinations thereof.
[0156] Linoleic acid
[0157] In certain embodiments, the animal food compositions and / or kits described herein may include linoleic acid. As used herein, the term "linoleic acid" refers to a polyunsaturated omega-6 fatty acid, (9Z, 12Z)-octadeca-9,12-dienoic acid, which is one of the two essential fatty acids for animals.
[0158] For measuring the linoleic acid content in a food composition, the skilled person may refer to any known technique. For example, a method by gas chromatography based on norm NF EN ISO 5508 / 5509 may be used.
[0159] In certain embodiments, an animal food composition or kit described herein comprises one or more substances that are a source of linoleic acid.
[0160] Sources of linoleic acid suitable for use in the present disclosure (i.e., materials containing linoleic acid) include, but are not limited to, vegetable oils, although animal oils or crude fats may also be used. In a particular embodiment, the source of linoleic acid (i.e., materials containing linoleic acid) includes safflower oil, sunflower oil, soybean oil, sesame oil, rapeseed oil (canola oil), other plant or animal oils / crude fats, meat, or a combination of two or more thereof.
[0161] In certain specific embodiments, the source of linoleic acid (i.e., a substance containing linoleic acid) included in the animal food composition or kit described herein is selected from the group consisting of safflower oil, sunflower oil, soybean oil, sesame oil, rapeseed oil, meat, or a combination thereof.
[0162] In certain embodiments, an animal food composition or kit described herein comprises linoleic acid in an amount of about 1 g / Mcal to about 20 g / Mcal, or in an amount of about 2% to about 10% by weight relative to the total weight of dry matter of the animal food composition.
[0163] In certain embodiments, linoleic acid is present in the animal food composition or kit in an amount of about 2 g / Mcal to about 20 g / Mcal, about 3 g / Mcal to about 20 g / Mcal, about 4 g / Mcal to about 20 g / Mcal, about 5 g / Mcal to about 20 g / Mcal, about 6 g / Mcal to about 20 g / Mcal, about 7 g / Mcal to about 20 g / Mcal, about 8 g / Mcal to about 20 g / Mcal, about 9 g / Mcal to about 20 g / Mcal, about 10 g / Mcal to about 20 g / Mcal, about 15 g / Mcal to about 20 g / Mcal, about 16 g / Mcal to about 20 g / Mcal, about 17 g / Mcal to about 20 g / Mcal, about 18 g / Mcal to about 20 g / Mcal, about 19 g / Mcal to about 20 g / Mcal, about 20 g / Mcal to about 20 g / Mcal, about 21 g / Mcal to about 20 g / Mcal, about 22 g / Mcal to about 20 g / Mcal, about 23 g / Mcal to about 20 g / Mcal, about 24 g / Mcal to about 20 g / Mcal, about 25 g / Mcal to about 20 g / Mcal, about 26 g / Mcal to about 20 g / Mcal, about 27 g / Mcal to about 20 g / Mcal, about 28 g / Mcal to about 20 g / Mcal, about 29 g / Mcal to about 20 g / Mcal, about 30 g / Mcal to about 20 g / Mcal, about 31 g / Mcal to about 20 g / Mcal, about 32 g / Mcal to about 20 g 0g / Mcal, about 11g / Mcal to about 20g / Mcal, about 12g / Mcal to about 20g / Mcal, about 13g / Mcal to about 20g / Mcal, about 14g / Mcal to about 20g / Mcal, about 15g / Mcal to about 20g / Mcal, about 16g / Mcal to about 20g / Mcal, about 17g / Mcal to about 20g / Mcal, about 18g / Mcal to about 20g / Mcal, about 19g / Mcal to about 20g / Mcal, about 1g / Mcal to about 19g / Mcal, about 1g / Mcal to about 18g / Mcal, about 1g / Mcal to about 17g / Mcal, about 1g / Mcal to about 16g / Mcal, from about 1g / Mcal to about 15g / Mcal, about 1g / Mcal to about 14g / Mcal, about 1g / Mcal to about 13g / Mcal, about 1g / Mcal to about 12g / Mcal, about 1g / Mcal to about 11g / Mcal, about 1g / Mcal to about 10g / Mcal, about 1g / Mcal to about 9g / Mcal , about 1g / Mcal to about 8g / Mcal, about 1g / Mcal to about 7g / Mcal, about 1g / Mcal to about 6g / Mcal, about 1g / Mcal to about 5g / Mcal, about 1g / Mcal to about 4g / Mcal, about 1g / Mcal to about 3g / Mcal, about 1g / Mcal to about 2g / Mcal, about 2g / Mcal to about 19g / Mcal, about 5g / Mcal to about 15g / Mcal, about 7.5g / Mcal to about 12.5g / Mcal or about 10g / Mcal.
[0164] In certain embodiments, linoleic acid is present in the animal food composition or kit in an amount by weight of about 2% to about 10%, about 3% to about 10%, about 4% to about 10%, about 5% to about 10%, about 6% to about 10%, about 7% to about 10%, about 8% to about 10%, about 9% to about 10%, about 1% to about 9%, about 1% to about 8%, about 1% to about 7%, about 1% to about 6%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%, about 2% to about 9%, about 3% to about 8%, about 4% to about 7%, or about 5%, relative to the total weight of dry matter of the animal food composition.
[0165] EPA / DHA
[0166] In certain embodiments, the animal food compositions and / or kits described herein may include EPA / DHA. As used herein, the term "EPA / DHA" refers to a fatty acid or fatty acid mixture consisting of (i) only eicosapentaenoic acid (EPA), (ii) only docosahexaenoic acid (DHA), or (iii) a combination of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA).
[0167] Thus, an amount of "EPA / DHA" refers to EPA, or DHA, or a combination of EPA and DHA.
[0168] In certain embodiments, an animal food composition or kit as described herein comprises a combination of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a weight ratio of about 0.1 to about 100 EPA:DHA.
[0169] According to further embodiments, there is no specific requirement for the respective amounts of EPA and DHA present in the EPA / DHA combination. Illustratively, the weight / energy ratio of EPA to DHA can be in the range of 0.0001 to 1000 relative to the total weight of dry matter of the animal food composition.
[0170] In certain embodiments, the animal food compositions or kits disclosed herein comprise EPA / DHA in an amount of about 0.1 g / Mcal to about 7 g / Mcal, or in an amount of about 0.1% to about 5% by weight of EPA / DHA relative to the total weight of dry matter of the animal food composition.
[0171] In certain embodiments, EPA / DHA is present in the animal food composition or kit in an amount of about 0.1 g / Mcal to about 7 g / Mcal, about 0.5 g / Mcal to about 7 g / Mcal, about 1 g / Mcal to about 7 g / Mcal, about 1.5 g / Mcal to about 7 g / Mcal, about 2 g / Mcal to about 7 g / Mcal, about 2.5 g / Mcal to about 7 g / Mcal, about 3 g / Mcal to about 7 g / Mcal, about 3.5 g / Mcal to about 7 g / Mcal. / Mcal, about 4g / Mcal to about 7g / Mcal, about 4.5g / Mcal to about 7g / Mcal, about 5g / Mcal to about 7g / Mcal, about 5.5g / Mcal to about 7g / Mcal, about 6g / Mcal to about 7g / Mcal, about 6.5g / Mcal to about 7g / Mcal, about 0.1g / Mcal to about 6.5g / Mcal, about 0.1g / Mcal to about 6g / Mcal, about 0.1g / Mcal to about 5.5g / Mcal l, about 0.1g / Mcal to about 5g / Mcal, about 0.1g / Mcal to about 4.5g / Mcal, about 0.1g / Mcal to about 4g / Mcal, about 0.1g / Mcal to about 3.5g / Mcal, about 0.1g / Mcal to about 3g / Mcal, about 0.1g / Mcal to about 2.5g / Mcal, about 0.1g / Mcal to about 2g / Mcal, about 0.1g / Mcal to about 1.5g / Mcal, about 0.1g / Mcal to about 1g / Mcal, about 0.1g / Mcal to about 0.5g / Mcal, about 0.5g / Mcal to about 6.5g / Mcal, about 1g / Mcal to about 6g / Mcal, about 1.5g / Mcal to about 5.5g / Mcal, about 2g / Mcal to about 5g / Mcal, about 2.5g / Mcal to about 4.5g / Mcal, about 2.5g / Mcal to about 4.5g / Mcal, about 3g / Mcal to about 4g / Mcal or about 3.5g / Mcal.
[0172] In certain embodiments, EPA / DHA is present in the animal food composition or kit in an amount from about 0.1% to about 5%, about 0.5% to about 5%, about 1% to about 5%, about 1.5% to about 5%, about 2% to about 5%, about 2.5% to about 5%, about 3% to about 5%, about 3.5% to about 5%, about 4% to about 5%, about 4.5% to about 5%, about 0.1% to about 4.5%, about 0.1% to about 4%, about 0.1% to about 4%, about 0.1% to about 3.5%, about 0.1% to about 3%, about 0.1% to about 2.5%, about 0.1% to about 2%, about 0.1% to about 1.5%, about 0.1% to about 1%, about 0.1% to about 0.5%, about 0.5% to about 4.5%, about 1% to about 4%, or about 1.5% to about 3.5% by weight, relative to the total weight of the dry matter of the animal food composition.
[0173] Taurine
[0174] In certain embodiments, the animal food compositions and / or kits described herein may include taurine. Taurine is a non-essential amino acid extracted from meat and fish. It stimulates the production of glycosphingolipids in the skin by acting as a precursor molecule. Glycosphingolipids exhibit antimicrobial properties.
[0175] In certain embodiments, taurine according to the present disclosure refers to a compound having the structure
[0176] or a pharmaceutically acceptable salt and / or a racemic, enantiomeric, diastereomeric or tautomeric form thereof
[0177]
[0178] One of the formulas.
[0179] Lutein
[0180] In certain embodiments, the animal food composition and / or kit described herein may include lutein. As used herein, "lutein" refers to one of xanthophyll and known naturally occurring carotenoids. Lutein is a lipophilic molecule and is generally insoluble in water. Lutein is synthesized only by plants and, like other xanthophylls, is found in high concentrations in green leafy vegetables such as spinach, kale and yellow carrots. Lutein and zeaxanthin are isomers that differ only in the position of a double bond. The main natural stereoisomer of lutein is (3R, 3'R, 6'R)-β, ε-carotene-3,3'-diol ((3R, 3′R, 6′R)-beta, epsilon-carotene-3,3′-diol). Lutein exists in plants in the form of fatty acid esters, in which one or two fatty acids are bound to two hydroxyl groups.
[0181] In certain embodiments, lutein according to the present disclosure refers to a compound having the following structure:
[0182]
[0183] or a pharmaceutically acceptable salt and / or one of its racemic, enantiomeric, diastereomeric or tautomeric forms.
[0184] Vitamin E
[0185] In certain embodiments, the animal food compositions and / or kits described herein may include vitamin E. Vitamin E is a general term for several biologically similar compounds, including those known as tocopherols and tocotrienols, which have the same biological activity. The most biologically active biological form of vitamin E (also the most active antioxidant) in animal tissues is alpha-tocopherol. Vitamin E cannot be synthesized in vivo. Vitamin E prevents damage to cell membrane integrity, which can adversely alter cell and organelle function. Vitamin E according to one aspect of the present disclosure can be in any form. It can be liquid, semisolid or solid. It can be a tocopherol or a tocotrienol. It can be alpha-tocopherol, (dx or dl-oc) beta-tocopherol (d-, B or dl-), gamma-tocopherol (dot or dim), delta-tocopherol, alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol or delta-tocotrienol. In certain specific embodiments, vitamin E is alpha-tocopherol.
[0186] According to one embodiment, the source of vitamin E is not limited. In certain embodiments, the source of vitamin E includes vitamin E acetate (e.g., tocopherol acetate), vitamin E acetate adsorbate, or spray-dried vitamin E acetate. In certain specific embodiments, the source of vitamin E is synthetic, although natural sources may also be used.
[0187] In certain embodiments, vitamin E according to the present disclosure refers to a compound having the following structure:
[0188]
[0189] or a pharmaceutically acceptable salt and / or one of its racemic, enantiomeric, diastereomeric or tautomeric forms.
[0190] Supplemental ingredients, substances or additives
[0191] In some embodiments, an animal food composition or kit as described herein is nutritionally complete and may further comprise supplemental ingredients, substances or additives, such as protein, crude fat, crude fiber, nitrogen-free extracts (NFE), ash, minerals, vitamins or flavorings.
[0192] protein
[0193] In certain embodiments, the animal food composition or kit according to the present disclosure may also include a source of protein. In certain embodiments, the protein level is high enough to ensure maintenance of the animal's lean body mass. In certain embodiments, the animal food composition or kit according to the present disclosure may include one or more different sources of protein.
[0194] In certain embodiments, an animal food composition as described herein may include a variety of proteins included in the source of protein used in the manufacturing process.
[0195] In certain other embodiments, an animal food composition as described herein may comprise a variety of proteins from a variety of protein sources.
[0196] In certain embodiments, the protein is not hydrolyzed. In certain other embodiments, the protein can exist in at least partially hydrolyzed form, or even in completely hydrolyzed form. In certain embodiments, the animal food composition or kit according to the present disclosure can incorporate protein in the form of meat or animal-derived materials (such as but not limited to beef, chicken, turkey, lamb, fish, blood plasma, medullary bone, etc. or a combination thereof). In certain other embodiments, the animal food composition or kit as described herein can be meat-free. In certain embodiments, such meat-free compositions / kits include a source of meat substitute protein, such as soybeans, corn gluten or any other protein-containing soy products to provide a source of protein. In certain embodiments, the animal food composition or kit disclosed herein may include an additional source of protein, such as soy protein concentrate (soya protein concentrate), milk protein, gluten (gluten), etc.
[0197] Crude fat
[0198] An animal food composition or kit according to the present disclosure may also include a nutritionally appropriate amount of crude fat.
[0199] The expression "crude fat" used in this specification refers to one or more crude fats and / or one or more oils acceptable to any food, regardless of their consistency at room temperature, that is, regardless of whether the "crude fat" exists substantially in fluid form or substantially in solid form. According to the animal food composition or kit of the present disclosure, crude fat of animal and / or plant origin may be included. Crude fat can be supplied by any of a variety of sources known to those skilled in the art. Plant crude fat sources include, but are not limited to, wheat, sunflower, safflower, rapeseed, olive, borage, linseed, peanut, blackcurrant seed, cottonseed, wheat germ, corn germ, and oil and other plant crude fat sources derived from these. Animal sources include, for example, but are not limited to, chicken crude fat, turkey crude fat, beef crude fat, duck crude fat, pork crude fat, mutton crude fat, etc., fish oil or any meat, meat by-products, seafood, dairy products, eggs, etc. The crude fat content of food can be determined by a variety of methods known to those skilled in the art.
[0200] fiber
[0201] Fiber may optionally be included in the animal food compositions or kits disclosed herein. The expression "fiber" is used herein similarly to "dietary fiber" and should be interpreted as total fiber for the purposes of this disclosure, meaning that it includes soluble fiber and insoluble fiber. Soluble fiber, as used herein, refers to fiber that is resistant to digestion and absorption in the small intestine and undergoes complete or partial fermentation in the large intestine. In contrast, insoluble fiber, as used herein, refers to non-starch polysaccharides that are resistant to digestion and absorption in the small intestine and resistant to fermentation in the large intestine. Soluble fiber is believed to have a prebiotic effect by providing short-chain fatty acids as an energy source to colonocytes. Insoluble fiber is believed to be useful for transport and ballast effects. Non-limiting examples of fibers include a first group including beet pulp, guar gum, chicory root, psyllium, pectin, blueberries, cranberries, pumpkin, apples, oats, beans, citrus, barley or peas, and a second group including cellulose, whole wheat products, wheat oats, corn bran, flax seeds, grapes, celery, green beans, broccoli, potato peels, fruit peels, vegetable peels, peanut shells and soy fiber.
[0202] Nitrogen Free Extract (NFE)
[0203] In certain embodiments, the animal food compositions and / or kits described herein may include a nitrogen free extract (NFE). As used herein and as commonly recognized in the art, nitrogen free extract (NFE) refers to a soluble carbohydrate portion that may be optionally included in an animal food composition or kit disclosed herein. If present in an animal food composition or kit disclosed herein, NFE may include a variety of soluble polysaccharides, starches, gums, mucilages, and pectins. As commonly known in the art, NFE does not include the insoluble carbohydrate portion contained in crude fiber materials, which may be present in the food composition or kit disclosed herein in some embodiments.
[0204] Typically, the nitrogen-free extract content of a food composition is determined by subtracting the content of each of the other components (protein, crude fat, crude fiber, ash) from the total dry matter of the food composition.
[0205] In certain embodiments where the qualitative and quantitative characteristics of a food composition are expressed as energy density (e.g., metabolizable energy density in g / Mcal), the NFE content is determined by subtracting the energy value of each other component (protein, crude fat, crude fiber, ash) from the energy value of the entire food composition.
[0206] In certain embodiments where the qualitative and quantitative characteristics of a food composition are expressed as weight percentages (e.g., weight percentages based on the total weight of dry matter of the composition), the NFE content is determined by subtracting the weight percentages of the other components (protein, crude fat, crude fiber, ash) from the total weight of the food composition.
[0207] In certain embodiments, the qualitative and quantitative characteristics of a food composition are expressed as weight percentages (e.g., weight percentages based on the total weight of dry matter of the composition), and the NFE content is determined by subtracting the weight percentages of the other components (protein, fat, crude fiber, ash) from the total weight of the food composition.
[0208] carbohydrate
[0209] In certain embodiments, the animal food compositions and / or kits described herein may include carbohydrates. As used herein, the term "carbohydrate" refers to a mixture of polysaccharides and sugars that are metabolized into energy when hydrolyzed in vivo. The carbohydrate content in the food composition and / or kit can be determined by a variety of methods known to those skilled in the art. Carbohydrates can be provided in any of a variety of carbohydrate sources known to those skilled in the art, including starch (any variety of corn, wheat, barley, etc.), beet pulp (containing a little sugar), and psyllium.
[0210] starch
[0211] An important source of nitrogen-free extracts that may be optionally included in the animal food compositions and / or kits disclosed herein consists of starch. One skilled in the art will appreciate that a variety of starches are suitable for use in the compositions of the present disclosure.
[0212] As used herein, the term "starch" refers to a polysaccharide composed of straight-chain starch and amylopectin. Starch is present in many plant tissues in the form of granules, typically between 1 μm and 100 μm in diameter, depending on the plant source. Chemically, starch is a polysaccharide composed of α-D-glucopyranosyl units linked with α-D(1-4) and / or α-D(1-6) bonds, and consists of two molecular types: straight-chain starch, a linear glucan composed of approximately 1000 α-D(1-4) linked glucoses; and amylopectin, a branched glucan composed of approximately 4000 glucose units with branches present with α-D(1-6) bonds.
[0213] As used herein, starch includes various crystal structures of A-type, B-type and C-type starch, which contain different proportions of amylopectin. A-type starch is mainly found in cereals, while B-type starch is mainly found in tubers and starch rich in amylose. C-type starch consists of a mixture of A and B forms and is mainly found in beans.
[0214] Normally, digestible starch is broken down (hydrolyzed) in the small intestine by the enzymes alpha-amylase, glucoamylase, and sucrase-isomaltase to produce free glucose, which is then absorbed.
[0215] The starch included in the animal foods or kits disclosed herein can be composed of any starch suitable for dietary purposes.
[0216] In practice, the native starch contained in the starting materials used to prepare the animal food composition or kit as described herein is susceptible to change during the manufacturing process. The specified amount of starch contained in the animal food composition or kit described in the present invention is composed of the amount of starch contained in the total amount of raw materials provided for the production of the animal food composition or kit. However, the amount of starch contained in the animal food composition or kit disclosed herein is equal to the total amount of starch contained in the starting materials used to prepare the animal food composition or kit.
[0217] If not known in advance, the starch content of the starting materials used to prepare the animal food composition or kit described herein can be determined according to conventional techniques known in the art, and in particular according to known polarimetry, for example according to NF EN ISO 10520.
[0218] In certain embodiments where the starting material may also include modified starch or pregelatinized starch, the starch content may also be determined according to NF EN ISO 15914.
[0219] Ash
[0220] In certain embodiments, the food compositions and / or kits disclosed herein may include ash. Ash may include minerals, such as calcium, phosphorus, sodium, chloride, potassium, magnesium, or a combination thereof. Ash content, if specified as a result of an analytical measurement of an animal food composition or kit as described herein, is a measure of the total amount of minerals contained therein. Mineral content is a measure of the amount of a specific inorganic component contained therein, including calcium (Ca), sodium (Na), potassium (K), and chlorine (Cl).
[0221] It should be readily understood that each embodiment of an animal food composition or kit encompassed by the present disclosure comprises a plurality of ingredients, each ingredient being included in the composition or kit at a given weight percentage compared to the total weight of dry matter of the animal food composition.
[0222] In certain embodiments, the animal food composition or kit disclosed herein comprises protein, crude fat, one or more EPA / DHA sources, ash, fiber, NFE, and optionally one or more other ingredients, such as vitamins, minerals, etc., based on the total weight of the dry matter of the animal food composition or kit, wherein the sum of the weights of each ingredient contained therein is 100% by weight.
[0223] Animal food compositions and kits
[0224] The present disclosure further relates to an animal food composition or kit as described herein, which itself comprises:
[0225] (i) a source of glycyrrhizin, and
[0226] (ii) a source of one or more Curcuminoids.
[0227] According to a specific embodiment, when the composition is in the form of a kit, the kit may contain:
[0228] (i) a first portion comprising a source of glycyrrhizin; and
[0229] (ii) a second part comprising a source of one or more Curcuminoids.
[0230] The animal food compositions and kits described herein may be as described above.
[0231] In certain embodiments, the animal food composition comprises:
[0232] (i) a source of glycyrrhizin, in combination with (ii) a source of one or more Curcuminoids; wherein the animal food composition consists of kibble and / or the animal food composition further comprises a source of protein.
[0233] As described in detail elsewhere, in certain embodiments, the source of glycyrrhizin can consist of at least one genus Glycyrrhiza. In specific embodiments, the source of glycyrrhizin is Glycyrrhiza glabra root, e.g., licorice. In certain specific embodiments, the source of glycyrrhizin is licorice.
[0234] In certain embodiments, and as also described in detail elsewhere, the source of glycyrrhizin is present in the animal food composition in an amount of about 0.01 g / Mcal to about 0.1 g / Mcal, based on the total weight of dry matter of the animal food composition.
[0235] In certain embodiments, and as also described in detail elsewhere, the source of glycyrrhizin is present in the animal food composition in an amount of about 0.01% to about 10% by weight, based on the total weight of dry matter of the animal food composition.
[0236] In certain embodiments, the curcuminoids are compounds represented by the general formula (I), pharmaceutically acceptable salts thereof, stereoisomers thereof or tautomers thereof:
[0237]
[0238] Where R 1 and R 2 are independently selected from hydrogen, methoxy, methyl, hydroxyl and ethoxy.
[0239] In certain embodiments, the one or more Curcuminoids are selected from the group consisting of curcumin, demethoxycurcumin, bismethoxycurcumin and / or tetrahydrocurcumin, or a combination thereof.
[0240] In certain specific embodiments, the one or more Curcuminoids consist of Curcumin.
[0241] In certain embodiments, the sources of Curcuminoids Curcuma longa, Curcuma xanthorrhiza and Curcuma zedoania are some sources of Curcuminoids. In specific embodiments, the source of one or more Curcuminoids is turmeric.
[0242] Illustratively, in certain embodiments, and as also described in detail elsewhere, the amount of the source of Curcuminoids may be from about 0.01 g / Mcal to about 0.1 g / Mcal relative to the total weight of the dry matter of the composition.
[0243] Illustratively, in certain embodiments, and as also described in detail elsewhere, the source of Curcuminoids may be present in an amount of about 0.01% to about 10% by weight relative to the total weight of dry matter of the composition.
[0244] In certain embodiments, an animal food composition or kit as described herein consists of kibbles. In certain embodiments, an animal food composition or kit as described herein further comprises a source of protein.
[0245] In certain specific embodiments, the present disclosure relates to an animal food composition comprising:
[0246] (i) Sources of glycyrrhizin, and
[0247] (ii) a combination of one or more sources of Curcuminoids;
[0248] Therein, the animal food composition is kibble and / or the animal food composition further comprises a source of protein.
[0249] In certain embodiments, the animal food composition or kit consists of a nutritionally complete animal food composition.
[0250] In certain embodiments, the animal food composition or kit consists of a food supplement and / or a medicament.
[0251] In certain embodiments, the source of glycyrrhizin consists of licorice, and / or the source of one or more curcuminoids consists of turmeric.
[0252] In certain embodiments, the animal food composition or kit as described herein further comprises linoleic acid. In a specific embodiment, the source of linoleic acid is selected from the group consisting of safflower oil, sunflower oil, soybean oil, sesame oil, rapeseed oil, meat, or a combination thereof.
[0253] In certain other embodiments, the animal food composition or kit further comprises EPA / DHA, taurine, lutein, vitamin E, and / or combinations thereof.
[0254] In certain other embodiments, the animal food composition or kit comprises or consists of a dry, wet, and / or semi-moist food composition.
[0255] In certain other embodiments, the animal food composition or kit comprises:
[0256] - an amount of licorice of about 0.02 g / Mcal to about 1 g / Mcal, about 0.04 g / Mcal to about 0.07 g / Mcal, or about 0.054 g / Mcal, and
[0257] - Turmeric in an amount of about 0.05 g / Mcal to about 0.08 g / Mcal or about 0.68 g / Mcal.
[0258] In certain embodiments, an animal food composition or kit of the present disclosure comprises:
[0259] - an amount of licorice of about 0.02 g / Mcal to about 0.1 g / Mcal,
[0260] - turmeric in an amount of about 0.05 g / Mcal to about 0.08 g / Mcal,
[0261] - linoleic acid in an amount of about 8 g / Mcal to about 12 g / Mcal,
[0262] - EPA / DHA in an amount of about 1 g / Mcal to about 2 g / Mcal,
[0263] - taurine in an amount of about 1 g / Mcal to about 2 g / Mcal,
[0264] - Lutein in an amount of about 0.001 g / Mcal to about 0.002 g / Mcal, and / or
[0265] - Vitamin E in an amount of about 0.2 g / Mcal to about 0.3 g / Mcal.
[0266] Illustratively, in certain embodiments, an animal food composition comprises:
[0267] - The amount of licorice is about 0.054g / Mcal,
[0268] - Turmeric in an amount of about 0.068 g / Mcal,
[0269] - linoleic acid in an amount of about 10.5 g / Mcal,
[0270] - The amount of EPA / DHA is about 1.5g / Mcal,
[0271] - Taurine in an amount of about 1.2 g / Mcal,
[0272] - Lutein in an amount of about 0.0013 g / Mcal, and / or
[0273] -The amount of Vitamin E is about 0.244 g / Mcal.
[0274] In certain embodiments, the animal is a canine. In certain specific embodiments, the animal is a dog.
[0275] Preparation method of composition
[0276] The present disclosure also provides a method for making the animal food composition specified herein. The manufacturing process of the animal food composition includes any method known in the art.
[0277] Animal food compositions described herein can be made by mixing and kneading ingredients to make a consistent dough or meat paste that can be cooked. This also applies to liquids that are mixed and homogenized before the cooking step in the package. The production process of dry food embodiments is usually completed by baking and / or extrusion. The dough is usually fed into an expander and / or an extruder, which uses pressurized steam or water to cook the ingredients. When the dough is in the extruder, the dough is under extreme pressure and high temperature. The dough is then pushed through a die (a hole of a specific size and shape) and then cut off with a knife. The puffed dough pieces are passed through a dryer to make a coarse grind so that the moisture content drops to a determined target, thereby ensuring that the food is stable until eaten. The coarse grind can then be sprayed with fat, oil, minerals, vitamins, natural extract mixtures, palatants, and optionally sealed in a package.
[0278] The composition may be a dry food, a wet food or a semi-moist food as described in the present disclosure.
[0279] In certain embodiments, the present disclosure provides a method of preparing an animal food composition comprising a combination of (i) a source of glycyrrhizin and (ii) a source of one or more Curcuminoids; comprising the steps of:
[0280] a) combining a source of glycyrrhizin and a source of one or more curcuminoids to provide a mixture; and
[0281] b) heating the mixture.
[0282] In certain embodiments, the animal food composition produced by the methods described herein is a kibble.In certain embodiments, the animal food composition produced by the methods described herein includes a source of protein.
[0283] In a specific embodiment, a source of glycyrrhizin and a source of one or more curcuminoids are mixed in step a), and the ingredients are selected from the group consisting of a source of linoleic acid, EPA / DHA, taurine, lutein, vitamin E and combinations thereof.
[0284] In a specific embodiment, a source of glycyrrhizin and a source of curcuminoids are mixed with a component selected from the group consisting of a source of linoleic acid, EPA / DHA, taurine, lutein, vitamin E, protein, crude fat, fiber, and combinations thereof.
[0285] Therapeutic or non-therapeutic applications
[0286] In further embodiments, the present disclosure provides the use of an animal food composition or kit as described herein for preventing and / or treating allergic inflammatory skin diseases. In specific embodiments, the present disclosure provides the use of an animal food composition or kit as described herein for preventing and / or treating atopic dermatitis, including atopic dermatitis in canines and particularly dogs.
[0287] In certain embodiments, the present disclosure relates to an animal food composition or kit comprising:
[0288] (i) Sources of glycyrrhizin, and
[0289] (ii) a combination of one or more sources of Curcuminoids;
[0290] A method for preventing and / or treating allergic inflammatory skin diseases.
[0291] In certain other embodiments, the animal food compositions or kits of the present disclosure can be used in therapeutic or non-therapeutic methods for preventing and / or treating allergic inflammatory skin diseases.
[0292] As mentioned above, the allergic inflammatory skin disease can be selected from the group consisting of atopic dermatitis, flea allergy dermatitis, urticaria, angioedema, inhalation allergy, inhalation allergic dermatitis, food allergy dermatitis, contact dermatitis, miliary dermatitis, eosinophilic granuloma, head and neck pruritus and generalized pruritus. In certain specific embodiments, the allergic inflammatory skin disease is atopic dermatitis, including atopic dermatitis in canines, especially dogs.
[0293] As described in detail elsewhere herein and shown in the Examples, the animal food compositions or kits described herein have positive effects on three (3) outcomes associated with allergic inflammatory skin diseases, particularly atopic dermatitis and more particularly canine atopic dermatitis.
[0294] In certain other embodiments, the animal food composition or kit described herein is used in a method of preventing and / or treating an animal suffering from an allergic inflammatory skin disease. In a specific embodiment, the animal suffers from atopic dermatitis, such as canine atopic dermatitis.
[0295] In a specific embodiment, the animal food composition is used to prevent and / or treat atopic dermatitis.
[0296] In certain other embodiments, the animal food composition is used to prevent and / or treat canine atopic dermatitis.
[0297] In certain other embodiments, the animal food composition is used to reduce pruritus flares.
[0298] In certain other embodiments, the animal food composition is used to reduce CADESI-04 score.
[0299] In certain other embodiments, the animal food composition is used to reduce the dosage and frequency of medications required to control the condition of the allergic inflammatory skin disorder.
[0300] The present disclosure also includes a kit comprising a source of glycyrrhizin and a source of one or more curcuminoids for use in a method of preventing and / or treating an allergic inflammatory skin disease. In a specific embodiment, the allergic inflammatory skin disease is atopic dermatitis, such as canine atopic dermatitis.
[0301] The present disclosure also provides a therapeutic or non-therapeutic method for preventing and / or treating allergic inflammatory skin diseases in animals, the method comprising at least the step of feeding the animal with the animal food composition or kit according to the present disclosure.
[0302] In certain embodiments, the animal suffers from an allergic inflammatory skin disease. In certain embodiments, the animal suffers from atopic dermatitis. In certain specific embodiments, the animal is a dog suffering from canine atopic dermatitis.
[0303] As shown in the examples, the animal food composition or kit described herein allows the prevention or treatment of allergic inflammatory skin diseases, such as atopic dermatitis. Beneficial effects are obtained in animals in the following situations: (i) animals fed only with the food composition or kit described herein, (ii) animals partially fed with the composition food or kit described herein and another food composition, and (iii) animals using the food composition or kit as a supplementary food or medicine.
[0304] In certain embodiments, (ii) "portion" means that the animal food composition or kit comprises at least about 30% of the animal's diet, at least about 50% of the animal's diet, or even at least about 70% of the animal's diet, or even at least about 80% of the animal's diet, or even at least about 90% of the animal's diet.
[0305] In certain embodiments, the food compositions or kits described herein are provided to an animal, particularly a dog, on a daily basis.
[0306] In certain embodiments, the animal food composition or kit disclosed herein can be provided to the animal to be treated as the only nutritionally complete food during the treatment period. According to these embodiments, the nutritionally complete animal food composition or kit is provided to the animal every day during the treatment period.
[0307] In certain other embodiments, the animal food composition or kit described herein can be provided to the animal to be treated alternately with other animal food compositions. In certain embodiments, the other animal food composition is a nutritionally complete animal food composition, which can be selected from known animal food compositions, including a wide variety of commercial animal food compositions, such as a wide variety of commercial dog food compositions.
[0308] In certain embodiments, the animal food composition or kit is provided every other day, thus according to a schedule of every two days. In another aspect of these embodiments, the animal food composition or kit is provided according to a schedule of every three days, four days, five days, six days or seven days.
[0309] It should be understood that in the daily practice of feeding animals, especially dogs, animal owners cannot follow a systematic way of feeding animals with animal food compositions every day. In certain embodiments, when animals are fed with animal food compositions or kits described herein every few days, the beneficial effects of preventing or treating allergic inflammatory skin diseases, and in particular preventing or treating canine allergic dermatitis, are fully provided. In specific embodiments, feeding animals once every three, four, five, six or seven days results in reduced beneficial effects, which may require longer treatment times.
[0310] Without wishing to be bound by any particular theory, it is hypothesized that effective prevention or treatment of allergic inflammatory skin diseases, such as canine allergic dermatitis, requires that at least an animal food composition or kit as described herein can be provided to an animal, especially a dog, if the animal food composition or kit is provided to the animal every few days, such as every other day, every three days, every four days, every five days, every six days, or every seven days. In certain specific embodiments, the food composition or kit is provided to the animal every day.
[0311] The period of time for feeding with the animal food composition or kit described herein can range from a few weeks to several years, depending, among other things, on the severity of the allergic inflammatory skin disease (eg, atopic dermatitis).
[0312] As has been described elsewhere herein, in certain embodiments, treatment for a short period of time (eg, 1 month) can be sufficient to reduce itching.
[0313] In certain other embodiments, the animal food composition or kit is provided to the animal to be treated for a longer period of time, e.g., about 9 months or longer, or about 12 months or longer (i) according to a feeding schedule comprising providing the animal, particularly a dog, with only the animal food composition or kit described herein, or (ii) according to a schedule alternating between providing the animal with an animal food composition or kit described herein and an additional animal food composition.
[0314] The present disclosure also relates to a method for preventing and / or treating allergic inflammatory skin diseases in an animal suffering from the allergic inflammatory skin diseases, the method comprising at least the step of providing feeding advice, wherein the feeding advice comprises the animal food composition or kit defined in the present invention.
[0315] The present disclosure further relates to the use of a combination of a source of glycyrrhizin and a source of one or more curcuminoids for preparing a composition for treating allergic inflammatory skin diseases.
[0316] The present disclosure further relates to the use of a kit comprising a first part containing a source of glycyrrhizin and a second part containing a source of one or more curcuminoids; for preparing a composition for treating allergic inflammatory skin diseases.
[0317] Example
[0318] The subject matter disclosed herein will be better understood by reference to the following examples, which are provided as illustrations of the disclosure and not as limitations. The materials and methods used in the examples are summarized below.
[0319] A. Materials and Methods
[0320] A.1. Objectives
[0321] The purpose of this clinical trial is to evaluate the effect of a novel animal food composition and timing on PVAS, drug scores, and CADESI-04, and to assess actual efficacy for these 3 outcomes at 3, 6, and 9 months.
[0322] A.2. Materials and methods
[0323] dog
[0324] Privately owned atopic dogs with non-seasonal pruritus were included. The diagnosis of atopic dermatitis was made using standard criteria after exclusion of epizootic parasites. Dogs with active bacterial and / or yeast infections and individuals who had responded adequately to an elimination diet, i.e. dogs classified as food allergic dogs, were not included. Dogs receiving allergen-specific immunotherapy for less than 12 months or dogs controlled solely by this intervention were not included. Included dogs should have received ongoing epizootic parasite treatment and this treatment was continued throughout the study. Concomitant medication was allowed throughout the study to ensure optimal quality of life but required careful documentation.
[0325] Inclusiveness consultation, scoring and measurement methods
[0326] Included dogs were initially assessed for skin lesions and pruritus using the CADESI-04 and Hill pruritus visual analogue scale (PVAS) (Hill et al., 2007; Olivry et al., 2014), respectively.
[0327] Medications used in the last month before enrollment were recorded. Scores were determined using a previously published method (Litzlbauer P et al., 2014; Oral and subcutaneous therapy of canine atopic dermatitis with recombinant feline interferon omega). Briefly, this method involves assigning a score for each medication, dose, and frequency each month, and the final score is defined by adding all medication-related scores (see Table 1).
[0328] Additionally, the dog owners rated the quality of the fur on a scale of 0 to 10. The owners further rated the quality of the feces on a scale of 1 (liquid) to 5 (very dry).
[0329] A total of 40 dogs were included and assigned to one of two study groups, 20 dogs in the test group and 20 dogs in the placebo group.
[0330] food
[0331] The study was double-blind and placebo-controlled. The included dogs were randomly assigned to one of two study groups.
[0332] One group of dogs received the test food ( test ) while the other group received a premium food from the same company with the same basic ingredients (placebo: Comparison ).
[0333] As mentioned above, neither the owners nor the investigators knew whether a particular dog received the test composition or the placebo composition. Owners were instructed to feed their dogs only with the food provided throughout the study. Informed consent was signed. The protocol was approved by the local ethics committee.
[0334] Table 2. Tested compositions
[0335]
[0336] "% DM": weight percentage, based on the total weight of dry matter of the food composition
[0337] "g / Mcal": Metabolizable energy density, expressed as g / Mcal
[0338] "NFE": Nitrogen Free Extract
[0339] "Starch": The starch content is included in the NFE content of the food composition
[0340] Follow-up consultation and withdrawal
[0341] Follow-up consultations were conducted after 1 month (telephone), 3 months, 6 months, and 9 months. The first consultation (at 1 month) was to record any study-related questions and to record the medical score and PVAS. The consultations after 3, 6, and 9 months included a general examination of the dog, CADESI-04, PVAS, medication score (Medication Score), feces, and fur quality scores.
[0342] Dogs could withdraw from the study at any time for any reason. However, owners were encouraged to feed their dogs the same diet for at least three months. Owners who were dissatisfied with the efficacy of the diet provided were advised to keep their pets on the test diet for another six months, using a different name than the two initial diets to ensure blinding. The reasons for withdrawal were recorded. Dogs that consumed these diets for at least three months were considered in the analyses. For sick animals that did not complete the entire study, the last available data were used for the analysis (last data carry-forward procedure).
[0343] Outcome measures
[0344] At inclusion and at the end of the study, or during the last control visit (in case of early withdrawal), CADESI-04, PVAS, and medical scores were recorded for each dog. The mean scores of the two groups were compared using qualitatively analyzed feces and fur quality scores. Statistical analysis was performed using Graphpad Prism 7 software (La Jola, CA, USA). Reasons for pushouts and unexpected events were recorded.
[0345] Mean comparison
[0346] After checking the normal distribution of the data, parametric statistical methods were used. The mean CADESI-04, PVAS, and medication scores at inclusion were first compared to assess that the groups were not statistically significantly different. At study completion, the CADESI-04, PVAS, and medication scores were compared between the two groups (test group vs. (vs) control group) using the t-test. Finally, CADESI-04, PVAS, and medication scores were compared within the groups (inclusion vs. (vs) completion) using the paired t-test.
[0347] Percentage of dogs with a 50% reduction or return to baseline
[0348] For each score, the proportion of dogs in each group with at least 50% improvement was assessed. In addition, the proportion of dogs in both groups that recovered to normal, i.e., dogs with CADESI-04, PVAS, and medication scores less than 12, 2.5, and 5, respectively, was assessed.
[0349] Overall response assessment
[0350] The overall response to treatment was considered excellent when the scores for all 3 outcomes decreased by more than 50% simultaneously and good when two of the 3 outcome scores decreased by more than 50% while the other score remained stable. For each food, the proportion of dogs in these evaluation groups was calculated.
[0351] B. Results
[0352] B.1. Individual comparison
[0353] After checking the normal distribution of the data, parametric methods were used. The mean CADESI-04, PVAS, and medication scores at inclusion were first controlled to assess that the groups were not statistically significantly different. At study completion, the CADESI-04, PVAS, and medication scores were compared between the two groups (test group vs control group) using t-test. Finally, CADESI-04, PVAS, and medication scores were compared within the group (inclusion vs completion) using paired t-test (P < 0.05).
[0354] The actual values measured are shown in Tables 2a and 2b.
[0355] Table 2a
[0356] test initial 1 month 3 months 6 months 9 months CADESI-04 Mean 24.3 15.5 19.3 14.3 Median 19 12 6.5 8 PVAS Mean 5.5 4.5 3.1 3.8 2.5 Median 5.5 4.2 3 2.1 2.8 drug Mean 19.5 19.2 12.7 10.8 6.4 Median 20 20 10 5 5
[0357] Table 2b
[0358] Comparison initial 1 month 3 months 6 months 9 months CADESI-04 Mean 23.5 17.6 27.2 15.3 Median 16 13.5 5.3 7 PVAS Mean 4.7 4.7 4.2 4.2 3.2 Median 4.5 4.8 4.1 2.7 2 drug Mean 24.4 26.5 26.1 25 10 Median 25 30 25 11.2 10
[0359] Table 3 provides the statistical significance of individual comparisons within each diet group (test vs. control pairs) and comparisons between diet groups (test vs. control groups) at each time point.
[0360] Table 3
[0361] Time score Test pairing Control pairing Test vs. Control Month 1 PVAS 0.02 0.33 0.41 drug 0.18 0.33 0.07 Month 3 CADESI 0.0005 0.09 0.39 PVAS <0.0001 0.29 0.09 drug 0.006 0.22 0.006 Month 6 CADESI 0.06 0.33 0.29 PVAS 0.01 0.24 0.001 drug 0.007 0.3 0.003 Month 9 CADESI 0.004 0.28 0.49 PVAS 0.008 0.19 0.49 drug 0.01 0.06 0.21
[0362] Forty dogs were initially included. The number of dogs involved at each checkpoint was as follows:
[0363] 1 month: 36 dogs (19 test, 17 control)
[0364] 3 months: 31 dogs (17 test, 14 control)
[0365] 6 months: 24 dogs (12 test, 12 control)
[0366] 9 months: 21 dogs (9 test, 12 control)
[0367] Initially, the mean CADESI-04 in the test and control groups was 24.3 and 23.5, p: 0.83. The mean PVAS was 5.5 and 4.7, respectively, p: 0.27. The medication score was 19.5 and 24.4, respectively, p: 0.63. Therefore, both groups were considered equivalent.
[0368] In terms of CADESI-04, at the completion of the study (month 9), the mean CADESI-04 values in the control and test groups were 15.3 and 14.3, p. 0.35. However, the decrease was significant in the test group (24.3 to 14.3, p: 0.004), but not in the control group (23.5 to 15.3, p: 0.28).
[0369] Regarding PVAS, the between-group comparison at study completion (month 9) was not statistically significant (P.0.49), but pairwise analysis was highly significant in the test group (mean pruritus decreased from 5.5 to 2.5, p:0.008), but not in the control group (4.7 to 3.2, p:0.19).
[0370] Finally, the medication scores were compared and at the end of the study (month 9), the comparison between the two groups was also not significant (p: 0.21), but a similar trend was seen within the groups. In fact, in the test group, the reduction was from 19.5 to 6.4 (p. 0.01), while in the control group, the reduction was more limited (24.4 to 10, p: 0.06).
[0371] In the control group, 3 dogs, 1 dog, and 0 dogs had a 50% improvement in CADESI-04, PVAS, and medical scores, while in the test group these numbers were 8, 7, and 6 (53%, 47%, and 40%), respectively.
[0372] In terms of overall response, only 1 dog in the control group was considered good (no excellent), while in the test group, 5 dogs were excellent and another 2 were good, for an excellent or good response of 47%.
[0373] Finally, it is noteworthy that six dogs in the test group normalized on all three outcome scores, whereas no dog in the control group met this definition.
[0374] In summary, statistical analysis showed that the test diet had a significant effect on all 3 outcome measures at every time point (relative to time point zero) beyond 3 months. The control diet had no effect at any time point (relative to time point zero). The test diet also had a significant effect on the PVAS within the first month. In addition, there were significant differences between the diet groups for medication scores at 3 and 6 months and PVAS (itch) at 6 months.
[0375] B.2. Linear Mixed Models for All Metrics
[0376] Linear mixed models were used to assess the effects of diet, time, and the interaction of time and diet on CADESI-04, PVAS, and drug scores. Animal was modeled as a random term.
[0377] Logarithmic transformation was used when necessary to meet the statistical assumptions of the linear mixed model (normally distributed residuals and homoscedasticity). Post hoc multiple comparisons were performed using Tukey HSD. The significance level was set at 5%.
[0378] Statistical results
[0379] CADESI-04:
[0380] Excluding the data from time point 9, the M03 test group was lower than the M00 test group, with a significance of P=0.066.
[0381] PVAS (itching):
[0382] Including the data of time point 9, the M03 test group was lower than the M00 test group (P=0.0001).
[0383] Including the data of time point 9, the M09 test group was lower than the M00 test group (P=0.0043).
[0384] Excluding the data from time point 9, the M03 test group was lower than the M00 test group (P=0.0001).
[0385] Drug rating (medical rating):
[0386] Including the data of time point 9, the M06 test group was lower than the M00 test group (P=0.021).
[0387] Including the data of time point 9, the M09 test group was lower than the M00 test group (P=0.018).
[0388] Including the data of time point 9, the M03 test group was lower than the M00 test group (P=0.058).
[0389] Including the data of time point 9, the M09 test group was lower than the M01 test group (P=0.039).
[0390] Including the data of time point 9, the M06 test group was lower than the M01 test group (P=0.052).
[0391] Excluding the data from time point 9, the M06 test group was lower than the M00 test group (P=0.03).
[0392] B.3. Comprehensive Rating
[0393] CADESI-04, PVAS, and medication scores were combined in a single score variable. After performing a standardization process (mean centering and scaling), a composite score was calculated by averaging the three different outcome scores.
[0394] Statistical results
[0395] Excluding the data from time point 1 and including the data from time point 9, the M03 test group was lower than the M00 test group (P=0.0008).
[0396] Excluding the data from time point 1 and including the data from time point 9, the M09 test group was lower than the M00 test group (P=0.0052).
[0397] Excluding the data from time points 1 and 9, the M03 test group was lower than the M00 test group (P=0.0014).
[0398] ***
[0399] Although the subject matter disclosed in the present invention and its advantages have been described in detail, it should be understood that various changes, substitutions and modifications can be made herein without departing from the spirit and scope of the present application as defined in the appended claims. In addition, the scope of the present application is not intended to be limited to the specific embodiments of the processes, machines, manufactures and material compositions, means, methods and steps described in the specification. Those of ordinary skill in the art will easily understand from the disclosure of the subject matter disclosed in the present invention that the subject matter disclosed in the present invention can be utilized according to the subject matter disclosed in the present invention to perform substantially the same function or achieve substantially the same result as the corresponding embodiment described herein, and the processes, machines, manufactures, material compositions, means, methods or steps currently existing or developed in the future. Therefore, the appended claims are intended to include such processes, machines, manufactures, material compositions, means, methods or steps within their scope.
[0400] For any patents, patent applications, publications, product descriptions, and protocols cited throughout this application, the entire disclosures of these are incorporated herein by reference in their entirety for all purposes.
Claims
1. A canine food composition comprising, based on the total weight of the dry matter of the canine food composition: (i) 0.01% to 0.1% by weight of a source of glycyrrhizin, (ii) 0.01% to 0.1% by weight of a source of one or more Curcuminoids, and (iii) a combination of 2% to 10% by weight of linoleic acid; For use in a method for preventing and / or treating allergic inflammatory skin diseases, in, The one or more curcuminoid compounds are compounds of general formula (I), pharmaceutically acceptable salts thereof, tautomers thereof, or stereoisomers thereof: Among them, R 1 and R 2 are independently a hydrogen atom, a methoxy group, a methyl group, a hydroxyl group or an ethoxy group.
2. The canine food composition for use according to claim 1, wherein: The one or more curcuminoid compounds are selected from the group consisting of curcumin, demethoxycurcumin, methoxycurcumin, tetrahydrocurcumin and combinations thereof.
3. The canine food composition for use according to claim 1 or 2, wherein: The canine food composition consists of a nutritionally complete canine food composition.
4. The canine food composition for use thereof according to claim 1 or 2, wherein: (i) the source of glycyrrhizin consists of liquorice, and / or (ii) the source of one or more Curcuminoids consists of turmeric.
5. The canine food composition for use according to claim 3, wherein: (i) the source of glycyrrhizin consists of liquorice, and / or (ii) the source of one or more Curcuminoids consists of turmeric.
6. The canine food composition for use thereof according to claim 1 or 2, wherein: The canine food composition further comprises EPA / DHA, taurine, lutein, vitamin E, or a combination thereof.
7. The canine food composition for use thereof according to claim 3, wherein: The canine food composition further comprises EPA / DHA, taurine, lutein, vitamin E, or a combination thereof.
8. The canine food composition for use thereof according to claim 4, wherein: The canine food composition further comprises EPA / DHA, taurine, lutein, vitamin E, or a combination thereof.
9. The canine food composition for use thereof according to claim 5, wherein: The canine food composition further comprises EPA / DHA, taurine, lutein, vitamin E, or a combination thereof.
10. The canine food composition for use thereof according to claim 1 or 2, wherein: The allergic inflammatory skin disease is selected from the group consisting of atopic dermatitis, flea allergy dermatitis, urticaria, angioedema, inhalation allergy, inhalation allergic dermatitis, food allergy dermatitis, contact dermatitis, miliary dermatitis, eosinophilic granuloma, head and neck pruritus and generalized pruritus.
11. The canine food composition for use thereof according to claim 3, wherein: The allergic inflammatory skin disease is selected from the group consisting of atopic dermatitis, flea allergy dermatitis, urticaria, angioedema, inhalation allergy, inhalation allergic dermatitis, food allergy dermatitis, contact dermatitis, miliary dermatitis, eosinophilic granuloma, head and neck pruritus and generalized pruritus.
12. The canine food composition for use thereof according to claim 4, wherein: The allergic inflammatory skin disease is selected from the group consisting of atopic dermatitis, flea allergy dermatitis, urticaria, angioedema, inhalation allergy, inhalation allergic dermatitis, food allergy dermatitis, contact dermatitis, miliary dermatitis, eosinophilic granuloma, head and neck pruritus and generalized pruritus.
13. The canine food composition for use thereof according to claim 5, wherein: The allergic inflammatory skin disease is selected from the group consisting of atopic dermatitis, flea allergy dermatitis, urticaria, angioedema, inhalation allergy, inhalation allergic dermatitis, food allergy dermatitis, contact dermatitis, miliary dermatitis, eosinophilic granuloma, head and neck pruritus and generalized pruritus.
14. The canine food composition for use thereof according to claim 6, wherein: The allergic inflammatory skin disease is selected from the group consisting of atopic dermatitis, flea allergy dermatitis, urticaria, angioedema, inhalation allergy, inhalation allergic dermatitis, food allergy dermatitis, contact dermatitis, miliary dermatitis, eosinophilic granuloma, head and neck pruritus and generalized pruritus.
15. The canine food composition for use thereof according to claim 7, wherein: The allergic inflammatory skin disease is selected from the group consisting of atopic dermatitis, flea allergy dermatitis, urticaria, angioedema, inhalation allergy, inhalation allergic dermatitis, food allergy dermatitis, contact dermatitis, miliary dermatitis, eosinophilic granuloma, head and neck pruritus and generalized pruritus.
16. The canine food composition for use thereof according to claim 8, wherein: The allergic inflammatory skin disease is selected from the group consisting of atopic dermatitis, flea allergy dermatitis, urticaria, angioedema, inhalation allergy, inhalation allergic dermatitis, food allergy dermatitis, contact dermatitis, miliary dermatitis, eosinophilic granuloma, head and neck pruritus and generalized pruritus.
17. The canine food composition for use thereof according to claim 9, wherein: The allergic inflammatory skin disease is selected from the group consisting of atopic dermatitis, flea allergy dermatitis, urticaria, angioedema, inhalation allergy, inhalation allergic dermatitis, food allergy dermatitis, contact dermatitis, miliary dermatitis, eosinophilic granuloma, head and neck pruritus and generalized pruritus.
18. A kit, comprising: (i) a first portion comprising 0.01% to 0.1% by weight of a source of glycyrrhizin; (ii) a second part comprising 0.01% to 0.1% by weight of a source of one or more Curcuminoids; as well as (iii) 2 to 10% by weight of linoleic acid, For use in a method for preventing and / or treating allergic inflammatory skin diseases, Wherein, the one or more curcuminoid compounds are compounds of general formula (I), pharmaceutically acceptable salts thereof, tautomers thereof, or stereoisomers thereof: Among them, R 1 and R 2 are independently a hydrogen atom, a methoxy group, a methyl group, a hydroxyl group or an ethoxy group.
19. The kit according to claim 18, wherein: (i) the source of glycyrrhizin consists of liquorice, and / or (ii) the source of one or more Curcuminoids consists of turmeric.
20. The kit of claim 18 or claim 19, further comprising EPA / DHA, taurine, lutein, vitamin E and / or combinations thereof.
21. A canine food composition comprising, based on the total weight of dry matter of the canine food composition: (i) 0.01% to 0.1% by weight of a source of glycyrrhizin, (ii) 0.01% to 0.1% by weight of a source of one or more Curcuminoids, and (iii) a combination of 2% to 10% by weight of linoleic acid; in, The one or more curcuminoid compounds are compounds of general formula (I), pharmaceutically acceptable salts thereof, tautomers thereof, or stereoisomers thereof: Among them, R 1 and R 2 are independently a hydrogen atom, a methoxy group, a methyl group, a hydroxyl group or an ethoxy group, and wherein the canine food composition consists of kibble and / or the canine food composition further comprises a source of protein.
22. The canine food composition according to claim 21, wherein The canine food composition consists of a nutritionally complete canine food composition.
23. The canine food composition of claim 21 or 22, wherein: (i) the source of glycyrrhizin consists of liquorice, and / or (ii) the source of one or more Curcuminoids consists of turmeric.
24. The canine food composition of claim 21 or 22, further comprising EPA / DHA, taurine, lutein, vitamin E, and / or combinations thereof.
25. The canine food composition of claim 23, further comprising EPA / DHA, taurine, lutein, vitamin E, and / or combinations thereof.
26. A method for preparing a canine food composition according to any one of claims 21 to 25, comprising the steps of: a) combining a source of glycyrrhizin and a source of one or more curcuminoids to provide a mixture; and b) heating the mixture, Wherein, the one or more curcuminoid compounds are compounds of general formula (I), pharmaceutically acceptable salts thereof, tautomers thereof, or stereoisomers thereof: Among them, R 1 and R 2 are independently a hydrogen atom, a methoxy group, a methyl group, a hydroxyl group or an ethoxy group.
27. Use of a canine food composition for the manufacture of a medicament for preventing and / or treating allergic inflammatory skin diseases in a canine in need thereof, the canine food composition comprising, based on the total weight of the dry matter of the canine food composition: (i) 0.01% to 0.1% by weight of a source of glycyrrhizin, (ii) 0.01% to 0.1% by weight of a source of one or more Curcuminoids, and (iii) 2 to 10% by weight of linoleic acid, in, The one or more curcuminoid compounds are compounds of general formula (I), pharmaceutically acceptable salts thereof, tautomers thereof or stereoisomers thereof: Among them, R 1 and R 2 are independently a hydrogen atom, a methoxy group, a methyl group, a hydroxyl group or an ethoxy group.
28. The use according to claim 27, wherein The one or more curcuminoid compounds are selected from the group consisting of curcumin, demethoxycurcumin, methoxycurcumin, tetrahydrocurcumin and combinations thereof.
29. The use according to claim 27, wherein The source of glycyrrhizin is liquorice.
30. The use according to claim 27, wherein The canine food composition comprises licorice and turmeric.
31. The use according to claim 27, wherein The allergic inflammatory skin disease is selected from the group consisting of atopic dermatitis, flea allergy dermatitis, urticaria, angioedema, inhalation allergy, inhalation allergic dermatitis, food allergy dermatitis, contact dermatitis, miliary dermatitis, eosinophilic granuloma, head and neck pruritus and generalized pruritus.
32. The use according to claim 27, wherein The canine food composition further comprises EPA / DHA, taurine, lutein, vitamin E, or a combination thereof.
33. The use according to claim 27, wherein The canine is a dog.
